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There is currently no information available on the transfer of the second-line anti-TB drug, 
rifapentine and its metabolite, into breastmilk.  The subsequent implications to the breastfed 
infant, as well as consequences of long-term exposure to potentially sub-therapeutic drug 
levels with regards to the development of drug resistant bacteria is therefore not known. A 
liquid chromatography method with detection by mass spectrometry (LC-MS/MS) is 
described for the quantification of rifapentine and its metabolite, 25-O-desacetyl rifapentine 
in human breastmilk, using rifampicin-d3 as an internal standard. An AB Sciex 4000 mass 
spectrometer at unit resolution in the multiple reaction monitoring (MRM) mode was used 
to monitor the transition of the protonated precursor ions m/z 877.5, m/z 835.4 and m/z 
827.4 to the product ions m/z 151.1, m/z 453.2 and m/z 151.200 for rifapentine, 25-O-
desacetyl rifapentine and rifampicin-d3, respectively. Ions were produced using Electro spray 
ionisation (ESI) in the positive ionisation mode. An Agilent Poroshell 120 EC-C18 (4.6 x 50 mm, 
2.7 μm) column was used for chromatographic separation using an isocratic method of 
acetonitrile containing 0.1% formic acid and water containing 10% methanol and 0.1% formic 
acid (55:45, v/v), at a flow rate of 450 µl per minute. The retention times for rifapentine, 25-
O-desacetyl rifapentine and rifampicin-d3 were ~2.67, ~1.88 and ~1.96 minutes, respectively.   
The method was developed and validated according to FDA guidelines. The extraction method 
consisted of a combination of protein precipitation and C18 solid phase extraction. 
Rifapentine and 25-O-desacetyl rifapentine showed no significant carry over on the Agilent 
autosampler. The method was reproducible when analysed with human breastmilk from six 
different sources from Western Cape Maternity Breastmilk Bank.   
Rifapentine mean extraction yield was 84.2% (%CV = 1.7) and that of 25-O-desacetyl 
rifapentine was 71.1% (%CV = 10.8). Rifapentine had a mean process efficiency of 80.4% (%CV 
= 4.7) and that of 25-O-desacetyl rifapentine was 95.7% (%CV = 5.7). Intra- and inter day 
validations over 3 days were performed. The calibration curves fit a quadratic regression with 
1/x weighting over a concentration range of 2 – 2000 ng/ml for both rifapentine and 25-O-
desacetyl rifapentine based on the analyte/internal standard peak area ratios, the accuracy 
ranged from 92.9% to 105.5% for both rifapentine and 25-O-desacetyl rifapentine standards.  
The Quality Controls accuracy ranged from 97.4% to 106.0% for both rifapentine and 25-O-
desacetyl rifapentine. Stock solutions were shown to be stable for 69 days at -80°C. 
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Rifapentine and 25-O-desacetyl rifapentine were stable in human breastmilk for up to 72 
hours at approximately -80°C and -20°C, on benchtop for ~4.5 hours on ice and after three 
freeze-thaw cycles. Rifapentine and 25-O-desacetyl rifapentine were shown to be stable on the 
autosampler over a period of approximately 48 hours after which the entire batch could be reinjected. 
Autosampler stability revealed a decrease in peak area ratios, indicating that a partial batch cannot be 
reinjected after 48 hours in case of instrument failure. 
This method will be utilized in the analysis of patient samples from a clinical study in South 
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I. LIST OF ABBREVIATIONS 
% CV  Percentage Coefficient of Variation. Used to express Precision of an analytical 
procedure 
% Difference (% Bias)  The difference between analyte concentration against 
reference concentration expressed as a percentage 
  % Difference (% Bias) = (Found value – reference value / reference value) x 100 
% Accuracy (% Nominal)  Analyte concentration against the nominal concentration 
expressed as a percentage  
% Accuracy (% Nominal) = (Found value / Nominal value) x 100 
~   Approximately  
°   Degrees 
µg   Microgram 
µl   Microliter 
ACN   Acetonitrile 
C   Celsius 
Conc.   Concentration 
FDA   Food and Drug Administration 
g   Gram 
HPLC   High Performance Liquid Chromatography 
ISTD   Internal Standard 
LC-MS/MS  Liquid Chromatography with Tandem Mass Spectrometry  
LLE   Liquid-liquid extraction 
LLOQ   Lowest Limit of Quantification 
MeOH   Methanol 
x 
 
min   Minutes 
mg   Milligram 
ml   Millilitre 
N2   Nitrogen 
n   Number of determinants 
n/a   Not applicable 
ng   Nanogram 
PHREE  Phospholipid Removal Columns  
QC   Quality Control 
rcf   Relative centrifugal force 
rpm   Revolutions per minute 
sec   Seconds 
SOP   Standard Operating Procedure 
SPE   Solid Phase Extraction 
STDEV   Standard Deviation 
SS   Stock Solution 
STD   Calibration Standard 
ULOQ   Upper Limit of Quantification  
v/v   Volume per volume 
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Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis which predominantly 
affects the lungs, but can also affect the kidneys, brain and spine. There are two forms, namely latent 
and active TB. In latent TB, the immune system supresses the TB bacteria, but if the immune system 
is compromised TB can become active. Active TB makes a person sick and can spread through the air 
when a person coughs or sneezes. It is estimated that 2 billion people in the world have latent TB 
infection, therefore they harbour M. tuberculosis in a nonreplicating dormant stage in their tissues 
with 10% of people reactivating to active TB at some point in their life (Zumla, et al., 2015). The World 
Health Organization (WHO) reported that in 2017 an estimated 10.0 million people developed TB; 5.8 
million were men, 3.2 million were women and 1.0 million were children (WHO, 2018). India, 
Indonesia, China, Philippines, Nigeria, Pakistan and South Africa accounted for 27%, 8%, 9%, 6%, 4%, 
5% and 3%, respectively, of the TB cases (WHO, 2018). Of these cases, 9% were of Human 
Immunodeficiency Virus (HIV) co-infected individuals, of which 72% were in Africa (WHO, 2018). WHO 
Europe and America region were reported to each have 3% of the global cases (WHO, 2018). WHO 
reported that approximately 920 000 individuals infected with HIV developed TB and approximately 
300 000 individuals died from HIV-associated TB (WHO, 2018). However, concurrent use of 
antiretroviral (ARV) therapy and anti-TB drugs have significantly reduced the mortality rate of HIV/TB 
patients. Concurrent treatment of HIV and TB can be challenging due to potentially underlying patient 
comorbidities, toxicity and resistance, drug-related factors such as adherence to therapy and complex 
drug interactions (Regazzi, et al., 2014). HIV infected individuals are thought to be at a higher risk of 
developing drug-resistant TB (Suchindran, et al., 2009).      
Multidrug resistant TB (MDR-TB) is characterised by resistance to at least two of the first-line anti-TB 
drugs while extensively drug resistant TB (XDR-TB) is characterized by resistance to at least four anti-
TB drugs; these may include isoniazid, rifampin and any fluoroquinolones (Zumla, et al., 2015). 
Resistance can arise due to lack of treatment compliance by TB patients and sub-therapeutic drug 
levels, to mention a few. Surveillance data from the WHO reports that there are 4.1% new rifampicin-
resistant or MDR-TB cases while 19% are from cases of individuals who have previously been treated 
with TB (WHO, 2017). WHO estimated 558 000 individuals developed resistance to rifampicin and 82% 
were diagnosed with MDR-TB (WHO, 2018). An estimated 8.5% of TB cases were reported to be of 
XDR-TB (WHO, 2018).  
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1.2 Tuberculosis treatment 
Treatment of active TB requires combination therapy comprising of two months of isoniazid (INH), 
rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB) followed by four months of RIF and INH 
(Iacobino, et al., 2017). The recommended dosage for these first-line oral anti-TB drugs is 5 mg/kg 
once daily for INH, 10 mg/kg once daily for RIF, 25 mg/kg once daily for PZA and 15-25 mg/kg once 
daily for EMB (Zumla, et al., 2015). These first-line anti-TB drugs are used for the treatment of active 
TB based on their ability to target the bacterial cell and inhibit its growth. The mechanism of action 
for rifampicin is not clearly understood. It has been shown to inhibit the M. tuberculosis cellular 
process by binding to the bacterial β-subunit responsible for DNA-dependent RNA polymerase, 
resulting in transcriptional interference which subsequently results in cell death (Nusrath & Hanna, 
2017). Pyrazinamide is a pro-drug that is converted in the human body to pyrazinoic acid which enters 
the bacterial cell via passive diffusion causing cytoplasmic acidification, resulting in the inhibition of 
bacterial enzymes and membrane transport (Nusrath & Hanna, 2017). INH is a pro-drug that is 
acetylated by N-acetyl transferase to N-acetyl INH. It enters the bacterial cell via passive diffusion and 
inhibits the synthesis of the bacterial nucleic acids and cell wall lipids using isonicotinic-acetyl-
nicotinamide-adenine-dinucleotide (INH-NAPD) and adenosine diphosphoribose (NAD) adducts 
(Bardou, et al., 1998) (Timmins & Deretic, 2006). The mechanism of action of EMB is to inhibit the 
arabinosyl transferases responsible for the bacterial cell wall biosynthesis thus permitting the drug to 
freely penetrate the bacterial cell to kill the bacteria (Goude, et al., 2009). 
Latent TB requires nine months of INH treatment or three months of rifapentine once weekly together 
with INH, three to four months of INH and RIF or three to four months of RIF only (Dutta & Karakousis, 
2014) (Zumla, et al., 2015). To ensure compliance from TB patients, directly observed therapy (DOT) 
is applied where a health professional typically observes the patient taking the respective anti-TB 
drugs as scheduled and document the observation, allowing the patients to be monitored and data to 
be generated (Karumbi & Garner, 2015). The effectiveness of DOT in reducing treatment failure 
observed in some studies (Tian, et al., 2014) has not been replicated in others (Pasipanodya & Gumbo, 
2013). 
MDR-TB requires treatment with injectables for at least 8 months followed by 12-18 months of 
continuation phase (Zumla, et al., 2015). MDR-TB drugs are chosen based on drug-susceptibility and 
the injectables kanamycin and capreomycin are drugs to consider, together with the fluoroquinolones 
such as levofloxacin and moxifloxacin (Zumla, et al., 2015). Other anti-TB drugs such as cycloserine 
and ethionamide, together with PZA and EMB are considered in incorporating second-line anti-TB 
drugs in treatment regimens for MDR-TB (Zumla, et al., 2015). XDR-TB treatment is usually chosen 
according to bacterial susceptibility testing results (Heyckendorf, et al., 2014). XDR-TB requires 
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intensive treatment using a minimum of six active anti-TB drugs followed by four anti-TB drugs in the 
continuation phase (Zumla, et al., 2015). Treatment for MDR and XDR-TB can include the use of 
bedaquiline, linezolid, clofazimine, amoxicillin, imipenem, high-dose INH, thioacetazone and 
clarithromycin (WHO, 2014).  
The current struggle for TB treatment is limited access to rapid and affordable diagnostics, long 
duration of treatment, high costs and lack of compliance which often leads to drug resistance. The 
WHO has set a target to end the TB epidemic by 2035 and to achieve this they aim to expand the scope 
and reach of interventions, produce health and development policies and systems, and pursue 
innovative scientific knowledge (WHO, 2018). New anti-TB drugs have been developed to aid in 
reducing the TB epidemic and treatment duration, such as, pretomanid and bedaquiline (Zumla, et al., 
2015). Some drugs such as rifapentine, linezolid, moxifloxacin, meropenem and clofazimine (initially 
approved for treatment of leprosy) have been repurposed to treat TB as they have shown potential in 
clinical studies (Zumla, et al., 2015). Host-directed therapy (HDT) is being investigated as part of TB 
treatment and it is intended to target immune response with the purpose of controlling M. 
tuberculosis replication (Zumla, et al., 2015). A weakened immune system fails to eliminate TB 
infection, therefore HDT provides new ways of effectively eliminating TB infection while attempting 
to keep the immune system strengthened. HDT strategies aim to manage MDR- and XDR-TB cases, 
reduce inflammation and tissue damage related to TB infection and treat patients with comorbid or 
chronic diseases such as HIV and diabetes (Kolloli & Subbian, 2017). The Figure below shows various 





Figure 1.1: Host-directed therapy against M. tuberculosis 
(A) HDT drugs change the integrity of granuloma and enhance drug accessibility. (B) Some HDT drugs 
increase production of antimicrobial peptides, reactive oxygen and induce autophagy in infected cells. 
(C) HDT drugs prevent proinflammatory responses that decrease inflammation and tissue damage 
during active stage of TB infection. (D) HDT agents control cell-mediated immune responses including 
antigen-specific T cell responses. (E) Monoclonal antibody administration and other emerging HDT 
concepts for TB treatment. Abbreviations: VEGF, vascular endothelial growth factor; PBA, 
phenylbutyrate; CAMP, cathelicidin antimicrobial peptide; ATG5, autophagy-related protein 5; BECN1, 
beclin-1; AMPK, AMP-activated protein kinase; COX1/2, cyclooxygenase-1/2; GR, glucocorticoid 
receptor; PDE, phosphodiesterases; MMPs, matrix metalloproteinases; KLF, Kruppel-like factor; PD-1, 
programmed cell death 1 receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; LAG3, 
lymphocyte activation gene 3; LAM, Lipoarabinomannan (Kolloli & Subbian, 2017). 
1.3 Rifapentine and 25-O-desacetyl Rifapentine 
Rifamycins consist of rifampin, rifapentine and rifabutin (Chaisson, 2003) (Drew, 2018). They are 
deacetylated to 25-deacetyl rifamycins by human arylacetamide deacetylase ( (Nakajima, et al., 2011). 
They are mainly used for the treatment of TB infection and in some cases invasive staphylococcal 
infections (Forrest & Tamura, 2010). Rifamycins are used in combination therapy in TB treatment to 
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prevent development of resistance due to mutations in the rpoB gene (Drew, 2018). Rifamycins are 
inducers of cytochrome P450 enzymes such as CYP3A4, which result in a decrease in bioavailability 
and increase in the clearance of co-administered drugs (Drew, 2018) (Forrest & Tamura, 2010). 
Rifamycin adverse effects have been reported to include hematologic, central nervous system, 
gastrointestinal, dermatological, hepatitis and production of orange-red discoloured body fluids  
(Martinez, et al., 1999). Rifapentine will be discussed further as this was the drug studied for this 
project. 
Rifapentine is a derivative of rifamycin used for the treatment of pulmonary TB (Zurlinden, et al., 
2016). It induces three cytochrome P450 enzymes, namely; CYP3A4, CYP2C8 and CYP2C9 isozymes. 
Concomitant treatment with rifapentine can result in reduced serum concentrations of drugs that are 
metabolized by the CYP enzymes (Munsiff, et al., 2006). Rifapentine has a long half-life of 13.2 to 14.1 
hours and a minimal inhibitory concentration (MIC) of approximately 0.02 mg/ml (Zurlinden, et al., 
2016). Rifapentine works by inhibiting bacterial DNA-dependent RNA polymerase (Wehrli, 1983). It is 
metabolized mainly by the liver via hydrolysis and deacetylation to 25-O-desacetyl rifapentine and is 
excreted predominantly (70%) by biliary excretion (Reith, et al., 1998) (Munsiff, et al., 2006). 
Absorption of rifapentine improves when administered with food, which helps those patients with 
gastrointestinal problems, but decreases INH peak concentrations by 20 - 50% during combination 
therapy (Mannisto, et al., 1982) (Peloquin, et al., 1999) (Zent & Smith, 1995). Treatment of active TB 
with rifapentine requires 600 mg orally twice weekly for two months and once weekly during the 
continuation phase of four months (FDA, 2010). A study by Jindani et al. investigating high-dose 
rifapentine with moxifloxacin for pulmonary tuberculosis reported that rifapentine and moxifloxacin 
administered once weekly during the continuation phase of six months was noninferior to the 
standard daily administration (Jindani, et al., 2014). For latent TB, the FDA approved 10 mg/kg orally 
once or twice weekly and rifapentine has been combined with INH for three months once weekly 
(Nguta, et al., 2015). Rifapentine should be considered a first line TB drug under special conditions and 
the United States National TB treatment guidelines recommends rifapentine for the treatment of TB 
in selected patients (Blumberg, et al., 2003). Rifapentine combined with INH once a week in the 
continuation phase can be used to treat HIV-seronegative patients with noncavitary, drug-susceptible 
pulmonary tuberculosis who have negative sputum smears upon completion of the initial phase of 
treatment (Blumberg, et al., 2003). Treatment of HIV infected patients with rifapentine has been 
associated with rifamycin resistance (CDC, 2002) (Vernon, et al., 1999). Rifapentine can also be 
prescribed to patients who are resistant to streptomycin and/or ethambutol (CDC, 2002) (Vernon, et 
al., 1999).  
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In healthy volunteers both rifapentine and its metabolite are highly protein bound, namely 98% and 
93%, respectively (Burman, et al., 2001) (Egelund, et al., 2014). The free fraction is pharmacologically 
active and can be established by determining the total concentration compared to the fraction not 
bound to plasma proteins (Egelund, et al., 2014). In a study consisting of predominantly males (10 
mg/kg of body weight/dose), rifapentine free fraction was reported in Africans to be 1.39% while in 
non-Africans it was 0.59% (Egelund, et al., 2014). Free rifapentine maximum concentration (Cmax) 
was reported to be 0.14 µg/ml in Africans and 0.10 µg/ml in non-Africans (Egelund, et al., 2014). 25-
O-desacetyl rifapentine free fraction was reported in Africans to be 6.23% while in non-Africans it was 
2.44% (Egelund, et al., 2014). Free 25-O-desacetyl rifapentine Cmax was reported to be 0.42 µg/ml in 
Africans and 0.28 µg/ml in non-Africans (Egelund, et al., 2014). Total rifapentine mean Cmax was found 
to increase with dose; 12.2 µg/ml at 600 mg, 14.6 µg/ml at 900 mg and 18.6 µg/ml at 1200 mg (Wiener, 
et al., 2004). High rifapentine free fraction has been noted in patients with reduced body mass index 
(BMI), albumin concentrations and total concentration of rifapentine (Egelund, et al., 2014). 
Rifapentine area under the curve (AUC) was associated with sex, race, dose and plasma albumin 
concentrations using multivariate regression analyses (Wiener, et al., 2004). With increasing dosages 
of 600, 900 and 1200 mg the AUC increased to 1.39 and 1.61-fold while the half-life ranged from 14.4 
to 16.4 hours (Wiener, et al., 2004). Wiener et al. reported the AUC and Cmax to be lower in non-
Africans compared to Africans and in males compared to females which corresponded with what the 
Egelund et al. study found (Wiener, et al., 2004) (Egelund, et al., 2014). Increasing of dosages has been 
associated with decreased bioavailability, and it has been suggested this may be due to the ability of 
the drug to be saturated when transported across the gut wall, dose-dependent increase in hepatic 
or pre-systemic clearance, sampling error, and the solubility and dissolution of drugs co-administered 
with rifapentine (Dooley, et al., 2012).  
The structure of rifapentine and its metabolite are shown in Figure 1.2 below, where a cyclopentane 
group can be noted. The molecular weight of rifapentine (C47H64N4O12) is 877.045 g/mol and for its 




Figure 1.2:The structure of rifapentine and 25-O-desacetyl rifapentine 
Figure 1.3 below shows a schematic of the proposed disposition of orally administered Rifapentine 
based on a study conducted by Reith et al. 1998. It also shows the 3-formyl derivatives of rifapentine 
and its metabolite formed by non-enzymatic hydrolysis. The study indicates that following absorption 
of rifapentine from the gastrointestinal tract it can be metabolized not only in the liver but in other 
tissues including the blood. Rifapentine is mainly eliminated by biliary excretion, as indicated in the 
diagram, and to a lesser extent in the urine.  
  
Figure 1.3: Schematic of proposed disposition of orally administered rifapentine 
Abbreviations: R, rifapentine; DR, 25-O-desacetyl-rifapentine; FR, 3-formyl-rifapentine; FDR, 3-formyl-
25-O-desacetyl rifapentine (Reith, et al., 1998).  
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1.4 Transfer of drugs into breastmilk 
Breastmilk contains many biologically active components which have an essential role in infant growth 
and health (Villasenor, et al., 2014). Breastmilk also contains significant amounts of fats and proteins 
(Rezk, et al., 2007). Health benefits of breastfeeding to the infant include reduced risk of sudden infant 
death syndrome, type II diabetes and allergies, to mention a few (Ito & Lee, 2003). A mothers’ benefit 
from breastfeeding include an increased bond with the infant, increase in maternal levels of oxytocin 
and results in decreased postpartum bleeding and quicker uterine involution (Ito & Lee, 2003). When 
drugs enter breastmilk, they mostly exist based on maternal plasma level, therefore, when drug 
plasma levels decrease in the plasma the breastmilk levels also decrease (Ito, 2000). Protein binding 
also plays a significant role in the transfer of drugs into breastmilk. Most drugs circulate in the 
maternal plasma bound to the proteins, the most predominant of which is albumin. The unbound drug 
fraction diffuses into the breastmilk while the bound fraction remains in the maternal plasma (Ito, 
2000). Drugs with long half-lives or which have active metabolites able to penetrate breastmilk could 
result in greater potential exposure to the infant (Ito & Koren, 1994). It has been recommended that 
drugs suitable for administration to breastfeeding women include those with low bioavailability and 
low absorption (Ito & Koren, 1994). However, not all drugs transferred into breastmilk are transferred 
in clinically significant amounts and the drug may therefore not pose a risk to the infant (Hale, 2004). 
Therefore, physicians consider several factors before prescribing a drug to a breastfeeding mother, 
which include: the need for the drug by the mother, potential effects of the drug on milk production, 
amount of the drug excreted into the breastmilk, the extent of oral absorption by the breastfeeding 
infant and any potential adverse effects on the breastfeeding infant (Hale, 2004). The infant’s age is 
also a contributing factor as adverse effects associated with drug exposure through breastfeeding 
typically occur in neonates younger than 2 months and rarely in infants older than 6 months (Chaves 
& Lamounier, 2004). A ratio is used to determine the drug concentration in breastmilk and is calculated 
by comparing it to the drug concentration in maternal plasma. This is called the milk-to-plasma drug 
concentration (Ito & Lee, 2003). The effect of the drug is determined by the amount of milk the infant 
ingests and the therapeutic dose of the drug (Horn, 2015). The ratio varies over time and therefore a 
time averaged ratio is used to represent the drug’s kinetics unless the concentration in breastmilk is 
known to be similar to that in maternal plasma (Sachs, 2013) (Anderson, et al., 2003). If the relative 
infant dose (RID) is below 10% of the therapeutic dose it is considered safe unless the drug or its active 
metabolite accumulates (Ito, 2000). The RID is directly proportional to the milk-to-plasma ratio and 
inversely proportional to the drug clearance rate by the infant (Ito & Koren, 1994). Therefore, drugs 
with reduced clearance rate tend to result in high levels of exposure and drugs with increased 
clearance rate tend to result in low levels of exposure regardless of the milk-to-plasma ratio being 
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high (Horn, 2015). The ratio is calculated from an equation that takes into consideration the drug’s 
physical and chemical characteristics (Begg & Atkinson, 1992). The ratio does not provide information 
on the absolute amount of drug transferred to the milk (Ito, 2000). 
The equation is expressed as follows: 
RID = A × [(milk-to-plasma ratio)/CLI] × 100, where A is the average milk intake per kg per minute, CLI 
is the rate of drug cleared by the infant (ml/kg/minute). 
There is currently limited data available on the transfer of anti-TB drugs into breastmilk and the 
subsequent effect on a breastfeeding infant. To date, the only drugs for which safety has been shown 
during breastfeeding are isoniazid, rifampicin, streptomycin, kanamycin and cycloserine, the latter 
four drugs having minimal passage into breastmilk (Gupta, et al., 2016). For rifampicin, a related 
rifamycin antibiotic, breastmilk concentrations have been shown to be very low. Peak levels of 0.05% 
of rifampicin levels observed in plasma are found in breastmilk with standard dosing for TB treatment 
(CDC, 2002). No data is available for the second-line anti-TB drug, rifapentine. 
1.5 Liquid chromatography tandem mass spectrometry  
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) is a combination of High-
Performance Liquid Chromatography (HPLC) for separation capacity and Mass Spectrometry for the 
detection capacity, making LC-MS/MS highly sensitive and specific. The separation in the HPLC column 
is either on normal or reverse phase. In normal phase the mobile phase is more hydrophobic while 
the stationary phase is more polar. The opposite is true for the reverse phase. LC-MS/MS requires 
several essentials, namely an autosampler to introduce the sample into the mobile phase flow which 
is usually a combination of water and an organic solvent and carries the sample into the column. 
Degassers remove bubbles from the mobile phase and pumps deliver the mobile phase at a constant 
flow rate. A column is used for chromatographic separation and the retention of the analyte will 
depend on its affinity to the stationary phase. Separated species are sprayed into the Atmospheric 
Pressure Ion Source (API) where ions are formed in the gas phase and the mass analyser (i.e. 
Quadrupole, Ion trap, Time of Flight and Magnetic sector) sorts them according to their mass to charge 
ratio and the detector amplifies the signal from the ions of interest and gives rise to a chromatogram 
displaying the response against time. 
The diagram below from Abdelrahman et al. displays a typical LC-MS/MS system (Abdelrahman, et al., 
2018). Following analyte extraction, the eluent is injected into the HPLC column and sprayed into the 
Mass Spectrometer. Ions are produced (i.e. via Electrospray Ionization process which will be discussed 
later) and enter the mass analyser (i.e. Quadrupole) where Quadrupole 1 (Q1) scans precursor ions, 
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in Quadrupole 2 (Q2) (also known as collision cell) the ions undergo fragmentation and in Quadrupole 
3 (Q3) product ions are identified and scanned. The detector amplifies the signal produced by the 
product ions and generates a chromatogram. The data is processed, analysed and reported. 
 
Figure 1.4: Schematic displaying a typical Liquid Chromatography Tandem Mass Spectrometer system 
Ionization sources that are generally used are, Atmospheric Pressure Chemical Ionization (APCI), 
Electrospray Ionization (ESI) and Matrix-assisted Laser Desorption/Ionization (MALDI). For this project, 
ESI was utilized and its principle will therefore be discussed. In ESI, an electrical field is applied to the 
HPLC eluent, charged droplets are produced at the capillary tip, the charged droplets are desolvated 
by using heat and nebulising gas (i.e. nitrogen) to form coulombic fission and ions are produced in the 
gas phase (Ho, et al., 2003). To ensure efficient charged droplet formation, liquid surface tension, 
eluent flow rate and electrolyte concentration need to be maintained accordingly (Konermann, et al., 
2012). ESI produces multiple charged species which is why it can be used for analysing large molecules.  
Below is a diagram from Chem LibreTexts displaying how ions are formed in electrospray ionization 
(LibreTexts, 2017). The HPLC eluent is sprayed through the capillary tip (spraying nozzle) and the 
coulombic forces are increased due to the repulsion of anions or cations. As the number of anions or 
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cations increase, they cause the eluent meniscus to change shape thus forming a Taylor cone. The 
Taylor cone releases charged droplets containing the analyte of interest. The droplets are desolvated, 
reducing the solvent radius but not its charge. The Rayleigh limit is achieved when the droplet surface 
tension reaches equilibrium with the electrostatic repulsive forces. This causes the surface charges to 
come closer together as the droplet is further desolvated. The droplet undergoes coulombic fission 
(explosion) due to the surface charges stress and the charged analyte of interest enters the sample 
cone for further analysis in the Mass Spectrometer. 
 
Figure 1.5: Schematic representation of the Electrospray Ionization process 
1.6 Quantification methods for Rifapentine 
Bioanalytical assays have been published for the quantification of rifapentine and its metabolite, 
mainly in human plasma, by means of liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
Winchester et al. developed a multiplex method for the quantification of the rifamycin antibiotics, 
rifabutin, rifampin and, rifapentine, as well as their metabolites, in human plasma by means of LC-
MS/MS (Winchester, et al., 2015). The authors used protein precipitation with trifluoroacetic acid 
(TFA): acetonitrile (0.1:99.9, v/v) as the extraction method and an ACE®C18 (3 x 100 mm) column was 
used for chromatographic separation with water: acetonitrile (55:45, v/v) with 0.5% formic acid as the 
mobile phase (Winchester, et al., 2015). Parsons et al. developed and validated a bioanalytical method 
to quantify rifapentine from dried blood spot samples using LC-MS/MS analysis (Parsons, et al., 2014). 
To extract the analyte, they applied a protein precipitation method with 90:10 methanol: 50 mM 
ammonium formate buffer (v/v) containing 0.50 mg/ml ascorbic acid as the extraction solvent 
(Parsons, et al., 2014). 
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1.7 Drug analysis in breastmilk 
There have been bioanalytical assays developed and validated on ARV drugs in dried breastmilk spots 
using LC-MS/MS. To prepare dried breastmilk spots (DBMS) 30µl of human breastmilk were spotted 
onto Whatman 903 Protein Saver Cards (Olagunju, et al., 2015) (Olagunju, et al., 2015) (Waitt, et al., 
2017). DBMS is advantageous since lower volumes of breastmilk are used and requires simple sample 
storage (i.e. room temperature) and transport (Olagunju, et al., 2015). However, the disadvantage of 
DBMS is that consistency of the method is subject to accurate pipetting of the breastmilk and spotting 
it which may be difficult as breastmilk is white, and the spotting cards are usually also white (Waitt, et 
al., 2017).  
ARV drugs have also been quantified in the liquid form of the breastmilk. Rezk et al. used 200 µl of 
breastmilk to extract ARV drugs lamivudine, zidovudine, stavudine, nevirapine, nelfinavir and lopinavir 
(Rezk, et al., 2007) (Rezk, et al., 2008). Rezk et al. encountered problems such as ion suppression and 
enhancement due to matrix effects, carry-over and a limited calibration range with using breastmilk 
in liquid form (Rezk, et al., 2008) (Rezk, et al., 2007). To overcome problems due to lipids and protein 
in the samples, extensive sample clean-up was applied by adding a greater volume (125 µl) of penta-
fluoropropionic acid to dissociate fat globules (Rezk, et al., 2008). It was difficult to eliminate the fats 
as the lipids and proteins are closely linked in breastmilk (Rezk, et al., 2008). A clean sample enables 
reproducibility and prevents column degradation (Rezk, et al., 2007). Rezk et al. used two methods, a 
combination of protein precipitation with SPE and liquid-liquid extraction with SPE which allowed the 
accurate quantification of the ARV drugs (Rezk, et al., 2007) (Rezk, et al., 2008). In solid phase 
extraction the authors found that increasing the percentage of the organic solvent (90% MeOH) to 
elute the analytes was sufficient and it enabled an increase in extraction efficiency (Rezk, et al., 2008). 
Having a wide calibration range (10-10 000 ng/ml) enabled accurate quantification of the analytes 
(Rezk, et al., 2008). For optimal extraction results, Rezk et al. recommend a wide calibration range for 
the method and for the calibration standards and quality controls to be prepared using intermediate 
stock solutions and not serial dilutions (Rezk, et al., 2008). Spiking the ARV drugs in breastmilk 
homogenized at room temperature and mixing well by gentle agitation enabled optimal extraction 
results (Rezk, et al., 2008). Lastly, constant mixing of samples during aliquoting ensured equilibration 
of the analytes and the lipids at different concentration levels used for the calibration range (Rezk, et 
al., 2008). Comparing analysis of drugs in DBMS, skim milk and whole breastmilk, whole breastmilk 
analysis is of clinical significance for accurate pharmacokinetic and pharmacodynamic predictions as 
the drugs partition through the various components of breastmilk (i.e. lipids) and the infants ingest 
whole breastmilk  (Rezk, et al., 2008). 
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No validated LC-MS/MS methods have been published for the quantification of rifapentine and 25-O-




2 Project Rationale, Aim and Objectives 
2.1 Rationale  
There is no data on the use of Rifapentine in breastfeeding women, its transfer into breastmilk, the 
effect on the infant, if the concentration levels are of clinical significance to the breastfed infant and 
the effects of long-term exposure to sub-therapeutic drug levels and the potential development of 
drug resistance. This prevents health professionals from making evidence-based recommendations on 
the optimal TB drug regimens for breastfeeding mothers. The assay will be used to analyse clinical 
samples and data generated will be used to interpret and evaluate clinically significant amounts (if 
any) of rifapentine transferred into breastmilk. Developing a sensitive and robust LC-MS/MS method 
that will be compatible with complex biological fluids such as breastmilk is of importance to the study 
to attain reliable data.  
2.2 Aim 
To develop and validate a bioanalytical assay for the quantitation of the anti-tuberculosis drug, 
rifapentine and 25-O-desacetyl rifapentine, in human breastmilk. 
2.3 Objectives  
• To develop a suitable extraction method of rifapentine and 25-O-desacetyl rifapentine 
from breastmilk 
• To develop a robust LC-MS/MS method for rifapentine and 25-O-desacetyl rifapentine 




3 Assay development 
3.1 Method development 
Developing a sensitive and robust extraction and LC-MS/MS method is of utmost importance to obtain 
reliable data. Effective sample pre-treatment is therefore required before the sample is injected onto 
the LC-MS/MS to remove endogenous components that may interfere with the ionization process of 
the analyte of interest, result in HPLC and autosampler blockages or contaminate the instrument over 
time due to residual proteins or salts. It is also important to ensure that the extraction solvent used is 
suitable for efficient analyte extraction. The most commonly used sample preparation methods are, 
protein precipitation, Liquid-liquid extraction (LLE) and Solid phase extraction (SPE). 
3.2 Mass spectrometer optimisation 
The source parameters of an API 3000 mass spectrometer were optimized for rifapentine and its 
metabolite, which included nebulising gas, turbo gas, curtain gas, collision gas, source temperature, 
ion spray voltage by means of flow injection analysis.  
3.3 Chromatography development  
The analytes (rifapentine and 25-O-desacetyl rifapentine) and potential internal standards (rifampicin-
d3, 25-desacetyl rifampicin-d3 and rifaximin) were infused on an API 3000 (AB Sciex) at a 
concentration of 200 ng/ml for the analytes and 80 ng/ml for the internal standards. For 
chromatographic separation, a Poroshell C18 column (4.6 x 50 mm, 2.7 μm) was used and the mobile 
phase applied was acetonitrile: 0.1% formic acid in water: methanol (60: 30: 10, v/v/v) with a flow rate 
of 300 µl/min. The initial analytical run time was 10 minutes but was later reduced to 3 minutes by 
decreasing the scan time and increasing the flow rate to 450 µl/min. Figure 3.1 shows a chromatogram 
of the analyte, metabolite and three potential internal standards with a flow rate of 300 µl/min and 
an analytical run of 10 minutes while Figure 3.2 shows a chromatogram of the analyte, metabolite and 
one internal standard (chosen for providing optimal quantification of rifapentine and its metabolite) 




Figure 3. 1: Representative initial chromatogram of the analytes and internal standards 
 
Figure 3. 2: Representative chromatogram of the analytes and internal standard – reduced run time 
3.4 Extraction development  
3.4.1 Protein precipitation and PHREE extraction 
Protein precipitation is a simple and quick method aimed at removing proteins from the sample 
through the addition of a solvent, leaving denatured proteins to pellet at the bottom of the tube. This 
can be achieved by lowering the sample pH with the addition of an acid or by adding an organic solvent 
XIC of +MRM (12 pairs): 877.400/845.400 Da ID: Rifapentine 1 from Sample 1 (Stock 001) of 1002.wiff (Turbo Spray) Max. 1.7e5 cps.
























XIC of +MRM (12 pairs): 877.400/845.400 Da ID: Rifapentine 1 from Sample 1 (B) of 1004.wiff (Turbo Spray) Max. 1.7e4 cps.




































(for example methanol) to the sample which results in the proteins precipitating out of solution, 
usually followed by centrifugation at a high speed. 
The first extraction method performed was protein precipitation. Published methods of rifapentine 
and 25-O-desacetyl rifapentine in human plasma mainly used this form of sample preparation 
(Winchester, et al., 2015). Various breastmilk volumes, namely 50, 100 and 200 µl were investigated 
to determine the optimal volume from which to extract the analyte and metabolite. This was 
performed in triplicate per volume using 400 µl of acetonitrile as a precipitation solvent.  Figure 3.3 
below shows volume optimization of breastmilk.  
 
Figure 3. 3: Breastmilk volume optimization 
A volume of 100 µl of breastmilk was shown to achieve the highest recovery of rifapentine and 25-O-
desacetyl rifapentine. Rezk et al. found 200 µl of breastmilk to be sufficient in extracting the ARV 
drugs, as the large volume enabled the analytes to equilibrate well in the presence of endogenous 
components (Rezk, et al., 2007) (Rezk, et al., 2008). In this project a volume of 200 µl resulted in poor 
recovery of the analytes, possibly due to an abundance of endogenous matrix components that may 
have led to ion suppression and/or matrix effects (Rezk, et al., 2008). A volume of 50 µl was also not 
sufficient for the extraction of adequate quantities of rifapentine and its metabolite for the purposes 
of assay development.  
Different solvents were optimized to determine which was best suited for absolute recovery of 
rifapentine and 25-O-desacetyl rifapentine with the protein precipitation method. The following 
solvents were optimized: acetonitrile, methanol, a combination of acetonitrile and methanol (50:50, 
v/v), acetonitrile with water (95:5, v/v) containing 1 mg/ml ascorbic acid and methanol with water 
























v/v) and 1 mg/ml ascorbic acid was best suited to extract both rifapentine and 25-O-desacetyl 
rifapentine as this solvent combination resulted in the greatest recovery of the analyte and 
metabolite. 
 
Figure 3. 4: Precipitation solvent optimization for rifapentine and 25-O-desacetyl rifapentine. 
Abbreviations: ACN - acetonitrile; MeOH - methanol; ACN: MeOH -acetonitrile and methanol (50:50, 
v/v); ACN: H2O – acetonitrile and water (95:5, v/v) with 1 mg/ml ascorbic acid; MeOH: H2O – methanol 
and water (95:5, v/v) with 1 mg/ml ascorbic acid  
Based on the data obtained above, the initial protein precipitation method used 100 µl of breastmilk 
spiked with rifapentine and 25-O-desacetyl rifapentine to which 400 µl precipitation reagent 
(acetonitrile: water (95:5, v/v) with 1mg/ml ascorbic acid) was added.  The sample was vortexed for 1 
minute, centrifuged at 13 000 g for 5 minutes, after which 450 µl of supernatant was transferred into 
a borosilicate tube. The sample was concentrated under nitrogen at 40°C for approximately 20 
minutes after which it was reconstituted in 200 µl injection solvent containing acetonitrile: 0.1% 
formic acid in water: methanol (60: 30: 10, v/v/v) and vortexed for 30 seconds. The sample was 
transferred into a 96-well plate and 5 µl was injected onto LC-MS/MS for analysis. 
Despite accurate calibration curves obtained using this protein precipitation method, residual fatty 
components were observed in the samples, making them incompatible with LC-MS/MS. This was 
similar to what Rezk et al. found when quantitating ARV drugs in breastmilk (Rezk, et al., 2007) (Rezk, 
et al., 2008). Therefore, further sample clean-up had to be applied. This led to the second extraction 
method investigated, namely protein precipitation with phospholipid removal columns (PHREE). 
PHREE (Phenomenex, USA) were incorporated in the protein precipitation method to eliminate excess 
proteins, lipids and phospholipids that could cause ion suppression or enhancement. As suggested by 

























the manufacturer’s instructions and with additional adaptations, for this method, 400 µl acetonitrile 
containing 0.1% formic acid and ascorbic acid (1 mg/ml) was used as the precipitating reagent which 
contained the investigational internal standard (rifampicin-d3) at 250 ng/ml. After concentration 
under nitrogen, the sample was reconstituted in 150 µl injection solvent (acetonitrile: 0.1% formic 
acid in water: methanol (60: 30: 10, v/v/v). The method followed is indicated below in Figure 3.5. 
 
Abbreviations: WS: Working solution; ACN: Acetonitrile: max speed = 20238 g; N2: nitrogen; LC-MS: liquid chromatography 
tandem mass spectrometry; ISTD: internal standard 
Figure 3. 5: Protein precipitation technique with PHREE columns 
Despite accurate calibration curves, sample clean-up appeared to be insufficient as matrix effects 
(data shown below in Table 3.4 1 and 3.4 2) were evident even though the sample appeared to be 
cleaner upon visual inspection. Matrix effects are caused by the presence of an unintended analyte or 
any other interfering compound in a biological sample that may interfere with the ionization process. 
The acceptance criteria for the matrix effects regression slope determined using an isotopically 
labelled analogue of the analyte as internal standard should not be more than 5%, while when using 
an internal standard that is not an-isotopically labelled analogue of the analyte the acceptance criteria 
for the regression slope should not be more than 10%. Matrix effects testing was used to test if the 
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Table 3.4 1: Matrix effects for rifapentine using protein precipitation with PHREE columns 
Table A: The peak areas for the analyte and internal standard at high, medium and low concentrations 
 













Matrix 1 35300000 4830000 22000000 5280000 729000 7050000 
Matrix 2 35100000 6390000 21600000 6710000 666000 6440000 
Matrix 3 35800000 5000000 22700000 5310000 747000 6050000 
Matrix 4 25900000 3180000 14700000 3270000 518000 3900000 
Matrix 5 27000000 6540000 15000000 6810000 545000 7440000 
Matrix 6 29300000 4020000 16700000 4810000 575000 5020000 
 
Table B: The peak area ratios and regression slope for each matrix 
 
High Conc. Medium Conc. Low Conc. Area Ratio 
1600 ng/ml 800 ng/ml 10.0 ng/ml v Conc. 
Peak Area Ratio Peak Area 
Ratio 
Peak Area Ratio Regression 
Slope 
Matrix 1 7.31 4.17 0.103 0.00453 
Matrix 2 5.49 3.22 0.103 0.00339 
Matrix 3 7.16 4.27 0.124 0.00442 
Matrix 4 8.14 4.50 0.133 0.00504 
Matrix 5 4.13 2.20 0.0733 0.00255 
Matrix 6 7.29 3.47 0.115 0.00451 
Average 6.59 3.64 0.109 0.00407 
STDEV 1.48 0.858 0.0207 0.000921 
% CV 22.5 23.6 19.1 22.6 






Table 3.4 2: Matrix effects for 25-O-desacetyl rifapentine using protein precipitation with PHREE 
columns 
Table A: The peak areas for the analyte and internal standard at high, medium and low concentrations  
 













Matrix 1 14400000 748000 8090000 765000 243000 887000 
Matrix 2 19700000 776000 12000000 774000 213000 769000 
Matrix 3 13600000 534000 7910000 559000 173000 616000 
Matrix 4 8460000 219000 4810000 225000 110000 27800 
Matrix 5 15500000 786000 9630000 755000 182000 795000 
Matrix 6 9910000 577000 6690000 690000 127000 683000 
 
Table B: The peak area ratios and regression slope for each matrix 
 
High Conc. Medium Conc. Low Conc. Area Ratio 
1600 ng/ml 800 ng/ml 10.0 ng/ml v Conc. 
Peak Area Ratio Peak Area 
Ratio 
Peak Area Ratio Regression 
Slope 
Matrix 1 19.3 10.6 0.274 0.00119 
Matrix 2 25.4 15.5 0.277 0.0158 
Matrix 3 25.5 14.2 0.280 0.0158 
Matrix 4 38.6 21.4 3.95 0.0218 
Matrix 5 19.7 12.8 0.228 0.0123 
Matrix 6 17.2 9.70 0.185 0.0107 
Average 24.3 14.0 0.867 0.0147 
STDEV 7.81 4.21 1.51 0.00407 
% CV 32.2 30.0 174.6 27.6 
Abbreviation: conc.: concentration; stdev: standard deviation 
The regression slopes for rifapentine and 25-O-desacetyl rifapentine were 22.6% and 27.6%, 
respectively, and therefore did not meet the acceptance criteria for matrix effects when using an 
internal standard that is not an isotopically labelled analogue of the analytes. These results indicated 
that matrix effects influenced the precision and accuracy of the assay. Liquid-liquid extraction was 
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therefore considered to achieve a cleaner sample with fewer endogenous interfering matrix 
components. 
3.4.2 Liquid-liquid extraction 
Liquid-liquid extraction (LLE) involves adding an organic (immiscible) solvent to an aqueous solvent 
which results in two immiscible layers. The aqueous and organic phase solvents were optimized to 
determine which solvent would result in better recovery of the analytes. The aqueous phase solvents 
optimized were ammonium acetate (100 mM, pH 4.81, pH adjusted by adding acetic acid), water, 
water with ascorbic acid (1 mg/ml) and ammonium bicarbonate (100 mM, pH 9.19). The organic phase 
solvents optimized were ethyl acetate, hexane and a combination of ethyl acetate and hexane (50:50, 
v/v). Figure 3.6 below show the optimization of the aqueous phase solvents for rifapentine and 25-O-
desacetyl rifapentine. 
 
Figure 3. 6: Aqueous phase extraction solvents optimized for rifapentine and 25-O-desacetyl 
rifapentine. 
Abbreviations: Amm. acetate – Ammonium acetate (100 mM) (pH 4.81); H2O - water; H20 + asc. acid – water with 1 mg/ml 
ascorbic acid; Amm. bicarbonate – Ammonium bicarbonate (100 mM) (pH 9.19) 
Water with ascorbic acid provided better recovery of rifapentine while water alone provided better 
recovery of 25-O-desacetyl rifapentine. However, water with ascorbic acid was chosen as the aqueous 
phase because ascorbic acid in general provides protection by preventing  oxidation (Bao, et al., 2008) 
and this combination showed a low coefficient of variation (%CV) for both rifapentine and 25-O-
desacetyl rifapentine in comparison to the water without ascorbic acid.  
Figure 3.7 below shows optimization of the organic phase solvents for Rifapentine and 25-O-desacetyl 
Rifapentine. 

























Figure 3. 7: Organic phase extraction solvents optimized for rifapentine and 25-O-desacetyl 
rifapentine. 
Figure legend: Ethyl acetate/hexane – (50:50, v/v) 
A combination of ethyl acetate and hexane (50:50, v/v) provided better recovery of rifapentine while 
ethyl acetate alone provided better recovery of 25-O-desacetyl rifapentine. However, a combination 
of ethyl acetate and hexane (50:50 v/v) was chosen as the organic phase as this combination showed 
consistency with a low percentage coefficient of variation (% CV) for both rifapentine and 25-O-
desacetyl rifapentine compared to ethyl acetate alone. 
The liquid-liquid extraction method was therefore finalized as follows: 100 µl of breastmilk spiked with 
rifapentine and 25-O-desacetyl rifapentine; 100 µl of aqueous solvent (water with 1 mg/ml ascorbic 
acid); 750 µl of organic solvent (ethyl acetate and hexane, 50:50, v/v) containing investigational 
internal standard at 250 ng/ml (rifampicin-d3); vortex for 1 minute; centrifuge at 13 000 g for 5 
minutes; freeze samples in a freeze-plate at approximately 30°C; pour off supernatant into borosilicate 
tubes; concentrate under nitrogen at 40°C; reconstitute in 200 µl injection solvent (acetonitrile: 0.1% 
formic acid in water: methanol (60: 30: 10, v/v/v); vortex for 30 seconds; transfer 200 µl into a 96-
microwell plate and inject 5 µl onto LC-MS/MS for analysis. 
The fatty components of the breastmilk resulted in the occasional sample-specific formation of 
emulsions. Furthermore, for samples in which two definitive immiscible layers formed, residual fatty 
substances were observed after sample concentration under nitrogen. Despite the liquid-liquid-
extraction resulting in cleaner samples than protein precipitation, matrix effects experiments (data 
























shown below in Table 3.4.3 and 3.4.4) indicated interference as a result of endogenous sample 
components.  
Table 3.4 3: Matrix effects for rifapentine using Liquid-liquid extraction 
Table A: The peak areas for the analyte and internal standard at high, medium and low concentrations  
 













Matrix 1 40300000 4430000 25300000 4720000 923000 6620000 
Matrix 2 39100000 5910000 25800000 6090000 862000 6550000 
Matrix 3 40000000 4790000 26600000 5440000 923000 6280000 
Matrix 4 31300000 3100000 18300000 3460000 681000 4260000 
Matrix 5 32000000 5540000 19200000 6840000 677000 7170000 
Matrix 6 35800000 4410000 21800000 4850000 781000 5120000 
 
Table B: The peak area ratios and regression slope for each matrix 
 
High Conc. Medium Conc. Low Conc. Area Ratio 
1600 ng/ml 800 ng/ml 10.0 ng/ml v Conc. 
Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
Matrix 1 9.10 5.36 0.139 0.00563 
Matrix 2 6.62 4.24 0.131 0.00408 
Matrix 3 8.35 4.89 0.147 0.00516 
Matrix 4 10.1 5.89 0.159 0.00625 
Matrix 5 5.78 2.81 0.0944 0.00357 
Matrix 6 8.12 4.49 0.153 0.00501 
Average 8.01 4.51 0.137 0.00495 
STDEV 1.59 0.943 0.0233 0.000986 
% CV 19.8 20.9 16.9 19.9 






Table 3.4 4: Matrix effects for 25-O-desacetyl rifapentine using Liquid-liquid extraction 
Table A: The peak areas for the analyte and internal standard at high, medium and low concentrations  
 













Matrix 1 2250000 120000 1080000 122000 35000 125000 
Matrix 2 2740000 115000 1830000 102000 33700 153000 
Matrix 3 2170000 80900 1610000 73800 30900 112000 
Matrix 4 1400000 36800 751000 30400 21000 32800 
Matrix 5 2670000 101000 1430000 96500 29700 136000 
Matrix 6 1710000 71800 1120000 81900 21400 105000 
 
Table B: The peak area ratios and regression slope for each matrix 
 
High Conc. Medium Conc. Low Conc. Area Ratio 
1600 ng/ml 800 ng/ml 10.0 ng/ml v Conc. 
Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
Matrix 1 18.8 8.85 0.280 0.0116 
Matrix 2 23.8 17.9 0.220 0.0148 
Matrix 3 26.8 21.8 0.275 0.0166 
Matrix 4 38.0 24.7 0.640 0.0235 
Matrix 5 26.4 14.8 0.218 0.0164 
Matrix 6 23.8 13.7 0.203 0.0148 
Average 26.3 17.0 0.306 0.0163 
STDEV 6.44 5.76 0.166 0.00395 
% CV 24.5 33.9 54.4 24.2 
Abbreviation: conc.: concentration; stdev: standard deviation 
The regression slopes of rifapentine and 25-O-desacetyl rifapentine were 19.9% and 24.2%, 
respectively. They therefore did not meet the acceptance criteria for matrix effects using an internal 
standard that is not an isotopically labelled analogue of the analytes.  This indicates that matrix effects 
influenced the precision and accuracy of the assay. For this reason, solid phase extraction was 
considered for sample clean-up. Furthermore, an API 4000 mass spectrometer (AB Sciex) was 
subsequently used for analysis due to instrument availability. 
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3.4.3 Mass spectrometer re-optimisation 
Parameters of an API 4000 mass spectrometer were optimized for rifapentine and its metabolite, 
which included nebulising gas, turbo gas, curtain gas, collision gas, source temperature, ion spray 
voltage and flow injection analysis.  
3.4.4 Chromatography re-development 
Rifapentine and 25-O-desacetyl rifapentine were infused onto an API 4000 Mass Spectrometer at a 
concentration of 100 ng/ml. Stock solutions were prepared at 1 mg/ml for the analytes and internal 
standard. In order to overcome the matrix effects observed for the protein precipitation and liquid-
liquid extraction, modifications were made to the mobile phase composition. Mobile phase A 
consisted of water: methanol (90:10, v/v) containing 0.1% formic acid and mobile phase B consisted 
of acetonitrile with 0.1 % formic acid. The analytical run time (Poroshell C18 column; 4.6 x 50 mm, 2.7 
μm) was 4 minutes with a flow rate of 450 µl/min and an isocratic mobile phase composition of 45% 
mobile phase A and 55% mobile phase B. Figure 3.8 below shows a representative chromatogram. At 
this stage, rifampicin-d3 was chosen as the most suitable internal standard in the absence of a stable 
isotopically labelled analogue for rifapentine and its metabolite. Dooley et al. and Parsons et al. used 
rifampicin-d3 as an internal standard to quantitate and validate rifapentine and its metabolite, and 
found that the internal standard compensated well during extraction and on-instrument (Parsons, et 
al., 2014) (Dooley, et al., 2012). Chromatography from the Parsons et al. study was similar to the 
chromatography displayed below where 25-O-desacetyl rifapentine eluted first followed by 




Figure 3. 8: Representative chromatogram for rifapentine and 25-0-desacetyl rifapentine 
3.4.5 Solid phase extraction development 
C18 SPE Vac cartridges (Waters Sep-Pak, 50 mg Silica) were used for Solid phase extraction (SPE). SPE 
provides effective sample clean up, is sensitive and selective, but it is time consuming. To determine 
which solvent would be appropriate for column conditioning, washing and eluting of rifapentine and 
25-O-desacetyl rifapentine, solvents were optimized, acetonitrile and methanol. Methanol was found 
to be the appropriate solvent for rifapentine and 25-O-desacetyl rifapentine. A published method 
describing SPE sample clean-up of rifampicin and levofloxacin in catheter segments from a mouse 
model of a device-related infection in which rifapentine was used as an internal standard was used as 
a guide to ensure effective sample clean-up (Bao, et al., 2008).  
The wash step was optimized to determine how many wash steps and what percentage of the organic 
solvent (methanol) can be applied to achieve effective elution of the analytes (Figure 3.9). Briefly, after 
each step of the SPE process, the resulting eluent was collected, evaporated to dryness, reconstituted, 
samples added to a 96 microwell plate and loaded into the sampler and quantified by means of LC-
MS/MS.   
Figure 3.9 below depicts wash step optimization (one wash for each tube) for rifapentine and 25-O-
desacetyl rifapentine. The column was conditioned with 1 ml methanol and equilibrated with 1 ml 
water before loading the sample, which had undergone prior protein precipitation and supernatant 
dilution. 
XIC of +MRM (9 pairs): 877.525/845.600 Da ID: RPT_1 from Sample 1 (SYS) of 1029.wiff (Turbo Spray) Max. 3.2e5 cps.


































Figure 3. 9: Wash step optimization for rifapentine and 25-O-desacetyl rifapentine. 
Abbreviations: T 1 -Tube 1, 900 µl of sample loaded; T 2- Tube 2, 1 ml H2O/MeOH (90:10, v/v); T 3 - 
Tube 3, 1 ml H2O/MeOH (80:20, v/v); T 4 - Tube 4, 1 ml H2O/MeOH (70:30, v/v); T 5 - Tube 5, 1 ml 
H2O/MeOH (60:40, v/v); T 6 - Tube 6, 1 ml H2O/MeOH (50:50, v/v); T 7 - Tube 7, 1 ml H2O/MeOH 
(30:70, v/v); T 8 - Tube 8, 1 ml H2O/MeOH (10:90, v/v); T 9 - Tube 9, 1 ml methanol (100%) 
The graph above indicates that when water: methanol 50:50 (v/v) is applied the analytes begin to 
elute from the SPE columns. This indicated that the wash step could contain a maximum of 40% 
methanol in order to remove endogenous matrix components. Optimizing the wash step also helped 
to determine the quantity and nature of the wash steps required to eliminate matrix effects, which 
were checked each time a wash step was optimized (data shown below in Table 3.4 5 and 3.4 6). There 
were two wash steps (wash 1: 90% water with 10% methanol; wash 2: 60% water with 40% methanol) 
implemented using solid phase extraction for the matrix effects results depicted below for both 


























Table 3.4 5: Matrix effects for rifapentine using Solid Phase Extraction 
Table A: The peak areas for the analyte and internal standard at high, medium and low concentrations  
 













Matrix 1 32100000 5130000 17600000 4870000 175000 5720000 
Matrix 2 31800000 4690000 16300000 5210000 175000 5710000 
Matrix 3 29100000 3740000 16800000 3930000 184000 4390000 
Matrix 4 36000000 3520000 20800000 3460000 170000 2690000 
Matrix 5 35500000 6530000 19900000 6570000 206000 8090000 
Matrix 6 18600000 3700000 10500000 4050000 140000 5150000 
 
Table B:  The peak area ratios and regression slope for each matrix 
 
High Conc. Medium Conc. Low Conc. Area Ratio 
1600 ng/ml 800 ng/ml 10.0 ng/ml v Conc. 
Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
Matrix 1 6.26 3.61 0.0305 0.00391 
Matrix 2 6.78 3.13 0.0306 0.00424 
Matrix 3 7.78 4.27 0.0419 0.00486 
Matrix 4 10.2 6.01 0.0632 0.00639 
Matrix 5 5.44 3.03 0.0254 0.00340 
Matrix 6 5.03 2.59 0.0271 0.00314 
Average 6.92 3.8 0.0365 0.00432 
STDEV 1.89 1.24 0.0143 0.00118 
% CV 27.4 32.8 39.1 27.3 








Table 3.4 6: Matrix effects for 25-O-desacetyl rifapentine using Solid Phase Extraction 
Table A: The peak areas for the analyte and internal standard at high, medium and low concentrations  
 













Matrix 1 21800000 1170000 9700000 932000 154000 815000 
Matrix 2 20800000 1270000 12100000 982000 135000 913000 
Matrix 3 15800000 820000 7480000 672000 91400 803000 
Matrix 4 14800000 454000 6260000 362000 44100 354000 
Matrix 5 26400000 986000 14100000 885000 192000 780000 
Matrix 6 15900000 803000 8630000 862000 133000 872000 
 
Table B: The peak area ratios and regression slope for each matrix 
 
High Conc. Medium Conc. Low Conc. Area Ratio 
1600 ng/ml 800 ng/ml 10.0 ng/ml v Conc. 
Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
Matrix 1 18.6 10.4 0.188 0.0116 
Matrix 2 16.4 12.3 0.147 0.0102 
Matrix 3 19.3 11.1 0.113 0.0120 
Matrix 4 32.6 17.3 0.124 0.0204 
Matrix 5 26.8 15.9 0.246 0.0167 
Matrix 6 19.8 10.0 0.152 0.0124 
Average 22.2 12.8 0.162 0.0139 
STDEV 6.16 3.05 0.0486 0.00388 
% CV 27.7 23.7 30.0 27.9 
Abbreviation: conc.: concentration; stdev: standard deviation 
Matrix effects influenced the precision and accuracy of the assay for rifapentine and 25-O-desacetyl 
rifapentine as the regression slopes were 27.3% and 27.9%, respectively. This did not meet the 
acceptance criteria for an internal standard that is not an isotopically labelled analogue of the analyte.  
Various publications have reported instability of rifamycins (Parsons, et al., 2014) (Fox, et al., 2011) 
(Dooley, et al., 2012) (Winchester, et al., 2015) (Melo, et al., 2011). Adding ascorbic acid during 
extraction helps to protect the analytes as it acts as an antioxidant (He, et al., 1996). Ascorbic acid 
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concentrations were investigated to determine the optimal concentrations that would protect 
rifapentine and its metabolite from oxidation. Figure 3.10 shows different ascorbic acid 
concentrations for rifapentine and 25-O-desacetyl rifapentine that were added with the precipitation 
reagent. 
 
Figure 3. 10: Optimization of ascorbic acid concentration for rifapentine and 25-O-desacetyl 
rifapentine. 
At 100 µg/ml the optimal effect of ascorbic acid is observed for rifapentine while 50 µg/ml is observed 
for 25-O-desacetyl rifapentine. An ascorbic acid concentration of 50 µg/ml provided consistency and 
a low percentage coefficient of variation (%CV) for both rifapentine and 25-O-desacetyl rifapentine, 
and the analyte peak areas for rifapentine were similar at both concentrations. Therefore, 50 µg/ml 
was the concentration that was chosen. 
The solid phase extraction method initially applied was as follows for sample preparation: 100 µl 
breastmilk; 10 µl working solution containing rifapentine and 25-O-desacetyl rifapentine; 200 µl 
methanol containing 250 ng/ml internal standard (Rifampicin-d3); vortex 30 seconds; sonicate 5 
minutes; vortex 10 seconds; centrifuge at 13 000 g for 5 minutes; transfer 250 µl supernatant into a 2 
ml tube and add 1.75 ml water containing 50 µg/ml ascorbic acid; vortex 10 seconds. Following sample 
preparation, the column was conditioned with 1 ml methanol, equilibrated with 1 ml water; 2 ml of 
the sample was loaded; 2 wash steps were applied - 1 ml of water and methanol (90:10, v/v) and 1 ml 
of water and methanol (70:30, v/v); the sample was eluted using 500 µl methanol containing 0.1 % 
formic acid. The samples were concentrated under nitrogen at 40°C, reconstituted in 150 µl of 
injection solvent (acetonitrile: 0.1% formic acid in water: methanol (60: 30: 10, v/v/v) and 5 µl was 
























This method produced cleaner samples compared to protein precipitation and liquid-liquid extraction 
methods, as expected. However, matrix effects were still evident (data shown below in Table 3.4 7 
and 3.4 8).  
Table 3.4 7: Matrix effects of rifapentine using Solid Phase Extraction 
Table A: The peak areas for the analyte and internal standard at high, medium and low concentrations  
 













Matrix 1 39100000 26200000 25900000 26000000 385000 26900000 
Matrix 2 39700000 27300000 26800000 27900000 378000 25800000 
Matrix 3 39800000 27700000 27000000 28300000 378000 26000000 
Matrix 4 42600000 29400000 28500000 28500000 363000 25600000 
Matrix 5 42400000 29300000 27500000 28700000 381000 26200000 
Matrix 6 29800000 14800000 18400000 15100000 273000 15300000 
 
Table B: The peak area ratios and regression slope for each matrix 
 
High Conc. Medium Conc. Low Conc. Area Ratio 
1600 ng/ml 800 ng/ml 10.0 ng/ml v Conc. 
Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression 
Slope 
Matrix 1 1.49 0.996 0.0143 0.000928 
Matrix 2 1.45 0.961 0.0146 0.000904 
Matrix 3 1.44 0.954 0.0145 0.000893 
Matrix 4 1.45 1.00 0.0141 0.000901 
Matrix 5 1.45 0.958 0.0145 0.000900 
Matrix 6 2.01 1.21 0.0178 0.00125 
Average 1.55 1.01 0.0150 0.000964 
STDEV 0.228 0.101 0.00139 0.000142 
% CV 14.7 10.0 9.3 14.8 




Table 3.4 8: Matrix effects of 25-O-desacetyl rifapentine using Solid Phase Extraction 
Table A: The peak areas for the analyte and internal standard at high, medium and low concentrations  
 














Matrix 1 25000000 26200000 15600000 26000000 207000 26900000 
Matrix 2 25300000 27300000 15400000 27900000 181000 25800000 
Matrix 3 24200000 27700000 15900000 28300000 184000 26000000 
Matrix 4 26900000 29400000 16600000 28500000 187000 25600000 
Matrix 5 27900000 29300000 15700000 28700000 190000 26200000 
Matrix 6 17000000 14800000 9420000 15100000 128000 15300000 
 
Table B: The peak area ratios and regression slope for each matrix 
 
High Conc. Medium Conc. Low Conc. Area Ratio 
1600 ng/ml 800 ng/ml 10.0 ng/ml v Conc. 
Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression 
Slope 
Matrix 1 0.954 0.600 0.00770 0.000595 
Matrix 2 0.927 0.552 0.00702 0.000578 
Matrix 3 0.874 0.562 0.00708 0.000545 
Matrix 4 0.915 0.582 0.00730 0.000571 
Matrix 5 0.952 0.547 0.00725 0.000594 
Matrix 6 1.149 0.624 0.00837 0.000717 
Average 0.962 0.578 0.00745 0.000600 
STDEV 0.0962 0.0300 0.000507 0.0000603 
% CV 10.0 5.2 6.8 10.0 
Abbreviation: conc.: concentration; stdev: standard deviation 
Matrix effects influenced the precision and accuracy of the assay for rifapentine as the regression 
slope was 14.8%, indicating it did not meet the acceptance criteria when using an internal standard 
that is not an isotopically labelled analogue of the analyte. The regression slope for 25-O-desacetyl 
rifapentine met the acceptance criteria when using an internal standard that is not an isotopically 
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labelled analogue of the analyte. However, since rifapentine failed to meet the acceptance criteria it 
necessitated further method development. For the results described above, two wash steps were 
incorporated, namely 1ml of water methanol 90:10 (v/v) and 1 ml of water methanol 70:30 (v/v). 
Therefore, the method was scrutinized and further optimized. The final method incorporated the two 
wash steps described above, but each was performed twice to remove interfering endogenous matrix 
components. 
The sample concentration step under a gentle, continuous stream of nitrogen was also optimized at 
different temperatures to determine the temperature best suited to concentrate the SPE eluent. 
Figure 3.11 below indicates the optimization of the concentration step for rifapentine and 25-O-
desacetyl rifapentine. 
 
Figure 3. 11: Sample concentration temperature optimization for rifapentine and 25-O-desacetyl 
rifapentine. 
As depicted on the graph above, applying increasing temperatures of 30°C and 40°C resulted in the 
degradation of the analytes regardless of the presence of ascorbic acid in the samples. However, a 
sample concentration temperature of 30°C was chosen as a compromise although it was clear that 
when no temperature was applied to the heating block there was better recovery of the analytes. This 
was done because the effect of the nitrogen being applied without temperature on the heating block 
resulted in the heating block becoming cold. The samples therefore took a long time to dry 
(approximately an hour and 30 minutes) while at 30°C it took approximately 30 minutes. The minimum 
temperature to which the heating block could be set was 30°C as per instrument design. 
























4 Final Assay 
4.1.1 Reagents and Chemicals   
Rifapentine (98.7% purity) was purchased from Sanofi (Bridgewater, New Jersey, United States) while 
25-O-desacetyl rifapentine (95.84% purity) and rifampicin-d3 (98% purity) was purchased from 
Toronto Research Chemicals (North York, Ontario, Canada). Methanol and ascorbic acid were 
purchased from Sigma-Aldrich (Darmstadt, Germany) while 2-Isopropanol and formic acid were 
purchased from Merck (Darmstadt, Germany). Acetonitrile was purchased from Honeywell 
(Pittsburgh, USA). LC-MS/MS grade Millipore water was produced in-house (Merck-Millipore, 
Germany). 
4.1.2 HPLC 
An Agilent Poroshell 120 EC-C18 column was used for chromatographic separation (4.6 x 50 mm, 2.7 
μm), the column temperature was set at approximately 30°C. An Agilent 1200 binary pump was used. 
An isocratic mobile phase of acetonitrile containing 0.1% formic acid (B) and water containing 10% 
methanol and 0.1% formic acid (A)  (55:45, v/v) was used at a flow rate of 450 µl/min and the run time 
was 4 minutes. An Agilent 1200 Autosampler set at approximately 8°C was used and a 5 µl injection 
volume was used to introduce the sample from a 96-well plate into the mass spectrometer.  
4.1.3 Mass Spectrometry 
An API4000 mass spectrometer with multiple reaction monitoring (MRM) in unit resolution (pause 
time 5 msec) was used and ions are produced using an ESI source in the positive ionisation mode. The 
nebuliser gas (Gas 1) (arbitrary unit) was set at 50 and turbo gas (Gas 2) (arbitrary unit) at 40. The 
curtain gas (arbitrary unit) was set at 30 and the collision gas (arbitrary unit) at 5. The source 
temperature was set at 350°C and the ion spray voltage at 5000 V. Flow injection analysis (FIA) was 
used to optimise the source settings. 
4.1.4 Quantitation parameters  
Analyst 1.6.2 software (Analyst Classic quantitation algorithm) was used to quantify rifapentine, 25-
O-desacetyl rifapentine and rifampicin-d3. The bunching factor for rifapentine, 25-O-desacetyl 
rifapentine and rifampicin-d3 was 1 while the smoothing factor for both rifapentine and rifampicin-d3 
was 3 and for 25-O-desacetyl rifapentine it was 5. Rifapentine elutes at approximately 2.70 minutes, 
25-O-desacetyl rifapentine at approximately 1.90 minutes and rifampicin-d3 at approximately 2.17 
minutes. The calibration curve fits a quadratic (weighted by 1/x) concentration regression over the 
range of 2 - 2000 ng/ml for both rifapentine and the metabolite based on the analyte/ISTD peak area 
ratios. Rifampicin-d3 internal standard was used to quantitate both rifapentine and its metabolite.  
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Protonated molecular ion 
mass (m/z) [M+H]+ 
877.5 835.4 827.4 
Product ion mass (m/z) 
Quantifier 
845.6 803.5 795.6 
Product ion mass (m/z) 
Qualifier 
151.1 453.2 n/a 
Dwell time (ms) 80 80 80 
De-clustering potential (V) 96 66 96 
Entrance potential (V) 10 10 10 
Collision energy (eV) 31 21 27 
Collision cell exit potential (V) 42 44 12 
Quantifier: most abundant product ions that are used to quantify an analyte peak. Qualifier: less abundant product ions used 
in monitoring an analyte of interest. 
4.2 Preparation of stock solutions, working solutions, calibration standards and 
quality controls 
4.2.1 Stock solution preparation (rifapentine and 25-O-desacetyl rifapentine) 
Stock solutions were prepared at 1 mg/ml in methanol (SS1 and SS1M). The weighed mass of the 
analytes was adjusted for purity. Stock solutions were stored at approximately -80°C until required. 
Stock solutions were used to prepare working solutions which were spiked into blank biological matrix. 
Stock solutions were tested for accuracy using HPLC UV. 








mass of analyte 
(mg) 
Adjusted* 





Methanol 1.234 1.250 1.234 1000 
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 
* Calculation: 1.25 x 0.987 
Table 4.2 2: Representative preparation of 25-O-desacetyl rifapentine stock solution (SS1M) 
Solvent  Volume of Weighed Adjusted* SS1M 
used solvent mass of analyte mass of analyte concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 0.786 0.820 0.786 1000 
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 





Table 4.2 3: Preparation of rifampicin-d3 stock solution (ISS1) 
Solvent  Volume of Weighed Adjusted* ISS1 
used solvent mass of analyte mass of analyte concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 0.500 0.500 0.500 1000 
* Reason for Adjustment (e.g. purity, salt, hydrate): None, volume of solvent was added directly to the vial 
4.2.2 Calibration standards preparation 
The 1mg/ml stocks of rifapentine and 25-O-desacetyl rifapentine are diluted 1:1 with methanol to a 
volume of 500 µg/ml. Working solutions (WS) are prepared volumetrically in MeOH: H2O (70:30, v/v). 
A volume of 48 µl of a 500 µg/ml stock of rifapentine and 25-O-desacetyl rifapentine are added to 995 
µl of blank solvent for WS1. Serial dilutions are then performed as shown in Table 4.2.4 below to 
obtain WS2 – WS11. Aliquots of 35 µl of each working solution were stored in 1.5 ml microcentrifuge 
tubes at approximately -80°C. When extracting calibration standards, 10 µl of WS were spiked into 
100 µl of blank breastmilk to obtain the concentrations of the calibration range depicted in Table 4.2.4. 
Calibration standards were spiked with WS on the day of extraction. For optimal extraction results, 
Rezk et al. recommend that the calibration standards and quality controls be prepared using 
intermediate stock solutions and not serial dilutions (Rezk, et al., 2008).  
4.2.3 Quality controls preparation 
Working solutions (WS) for QC samples are prepared volumetrically in MeOH: H2O (70:30, v/v), using 
the same methodology used to prepare working solutions for the calibration standards. To obtain WS 
Dilute, 148 µl of a 500 µg/ml stock of rifapentine and 148 µl of 25-O-desacetyl rifapentine are added 
to 1386 µl of blank solvent and serially diluted to obtain WS_H, WS_M, WS_SYS, WS_L, WS_LLOQ1 
and WS_LLOQ2, as depicted on Table 4.2.5. For the validation, the LLOQ was evaluated at two 
concentrations, namely 2 and 4 ng/ml. The assay performed well, and the API 4000 was sufficiently 
sensitive to accurately and reproducibly measure the analytes across a range of 2 to 2000 ng/ml during 
the inter- and intra-day validations.  Aliquots of 35 µl of QC working solutions (WS) were stored in 1.5 
ml microcentrifuge tubes at approximately -80°C. During an extraction 10 µl of the working solutions 
of QC H, M, L and LLOQ were spiked into 100 µl of blank breastmilk to obtain the concentrations of 
the calibration range depicted on Table 4.2.5. Quality Control were spiked with WS on the day of 
extraction due to the analytes precipitating out of solution when pre-spiked and stored at -80°C. 



































WS1 995 SS1 + SS1M 48 x 2 21998 100 10.0 STD1-ULOQ 2000 
WS2 200 WS1 600 16499 100 10.0 STD 2 1500 
WS3 400 WS2 400 8250 100 10.0 STD 3 750 
WS4 400 WS3 400 4125 100 10.0 STD 4 375 
WS5 434 WS4 400 1980 100 10.0 STD 5 180 
WS6 475 WS5 380 880 100 10.0 STD 6 80.0 
WS7 514 WS6 400 385 100 10.0 STD 7 35.0 
WS8 426 WS7 450 198 100 10.0 STD 8 18.0 
WS9 500 WS8 401 88.0 100 10.0 STD 9 8.00 
WS10 400 WS9 400 44.0 100 10.0 STD 10 4.00 
WS11 200 WS10 200 22.0 100 10.0 STD 11-LLOQ 2.00 





































SS1; SS1M 150 SS1; SS1M 150 n/a n/a n/a n/a n/a 
WS_ Dil 1386 SS1 + SS1M 148 x 2 43995 100 10.0 DIL 4000 
WS_ H 1050 WS_ DIL 700 17598 100 10.0 H 1600 
WS_ M 700 WS_ H 700 8799 100 10.0 M 800 
WS_ SYS 1350 WS_ M 150 880 100 10.0 SYS 80.0 
WS_ L 1500 WS_ SYS 100 55.0 100 10.0 L 5.00 
WS_ LLOQ 1 150 WS_ L 600 44.0 100 10.0 LLOQ 1 4.00 
WS_ LLOQ 2 250 WS_ LLOQ 1 250 22.0 100 10.0 LLOQ 2 2.00 
Abbreviation: Dil – Dilution; H – high; M – Medium; SYS – system suitability sample; L – low; LLOQ – lowest limit of quantification 
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4.3 Extraction method 
This is therefore the finalized extraction method below which is a combination of protein and solid 
phase extraction. This combination of extraction methods allowed for sufficient sample clean up 
before it is added to the SPE C18 columns. 
Sample preparation requires thawing blank breastmilk samples and vortexing for 1 minute. Working 
solutions for calibration standards and quality controls, as well as internal standard, were sonicated 
on ice (as it was observed that the analytes degrade at room temperature) for five minutes and 
vortexed for 30 seconds.  
Protein precipitation was performed on ice.  A volume of 100 µl of blank breastmilk was aliquoted into 
1.5 ml microcentrifuge tubes and 10 µl of appropriate working solution for calibration standards and 
quality controls was added into the 100 µl blank breastmilk. The blank and double blank samples 
receive 10 µl of blank solvent (MeOH: H2O, 70:30, v/v). To the 1.5 ml tubes, 250 µl of precipitation 
reagent (MeOH) containing Rifampicin-d3 (internal standard) at 250 ng/ml was added. The tubes were 
vortexed at maximum speed for 30 seconds, centrifuged for five minutes at 20238 g (maximum speed) 
and 300 µl of supernatant transferred into 2 ml microcentrifuge tubes. A volume of 1.5 ml of water 
was added and tubes vortexed for 10 seconds. 
SPE was performed at room temperature.  A volume of 1 ml methanol was used to condition the C18 
SPE Vac cartridges (Waters Sep-Pak, 50 mg Silica). The cartridges were equilibrated with 1 ml water. 
The sample was loaded in two 1 ml steps and eluted under positive pressure between the addition 
steps. The cartridges were washed twice with 1 ml H2O: MeOH (90:10, v/v). The cartridges undergo a 
second wash step, twice, with 1 ml H2O: MeOH (80:20, v/v). To elute the analytes, 500 µl of elution 
solvent (MeOH with 0.1 % formic acid and 50 µg/ml ascorbic acid) was added and eluted under 
positive pressure, collecting eluent in a glass borosilicate tube. The elution step was repeated, and the 
eluent collected into the same borosilicate tube. The sample was concentrated under nitrogen at 
approximately 30°C for approximately 30 minutes. To reconstitute, 200 µl of injection solvent 
containing mobile phase A and B (50:50, v/v) containing 20 µg/ml ascorbic acid was used and the 
sample was vortexed for 30 seconds. Samples were added to a 96 microwell plate and loaded into the 
sampler. Mobile Phase A contained H2O: MeOH: formic acid (90:10:0.1, v/v/v) and Mobile Phase B 




5 Assay validation 
A bioanalytical assay is validated to determine if it is robust, reproducible and reliable for the 
quantification of the analyte in a biological matrix. Validation experiments conducted should include, 
but not limited to, matrix effects, recovery, process efficiency, sensitivity and specificity, carry-over, 
cross-talk, stability and re-injection reproducibility (FDA, 2018). 
5.1.1 Inter- and intra-day validation 
Inter-day validation evaluates accuracy and precision over at least 2 days, while an intraday validation 
is evaluated by analysing accuracy and precision within a single run. Each validation consists of 
calibration standards in duplicate and quality control samples (QC’s) in sextuplicate, covering the 
entire calibration range for the analytes. Precision of inter and intraday validations should be less than 
15% for standards and QC samples at high, medium and low levels and less than 20% for the Lowest 
Limit of Quantification (LLOQ). At least 75% of standards and 67% of quality controls should meet the 
acceptance criteria of nominal concentration 85-115% and 80-120% for LLOQ. Furthermore, 50% of 
QC’s at each level should pass. Accuracy is described as the closeness to a determined value of the 
nominal concentration of the analyte while precision (Coefficient of Variation = %CV) is described as 
the closeness of more than one measurement to the analyte of interest (FDA, 2018).  
5.1.2 Stability assessments 
Stability was assessed under different conditions to determine if the analyte is affected by the 
conditions. The stability of stock and working solutions is evaluated to determine stability during 
storage and during expected duration on-bench. High and low QC samples are used to assess matrix 
stability and are spiked in blank matrix at the respective concentration (in sextuplicate). Analysis of 
the stability QC samples is done against a valid calibration curve from calibration standards spiked on 
the day of extraction and at each level the mean concentration should be within 15% of the nominal 
concentration. Freeze-thaw, matrix stability, stock and working solution stability, benchtop, 
reinjection reproducibility and autosampler stability is determined. 
5.1.2.1 Stock solution accuracy and stability  
Stock solution accuracy and stability was assessed to ensure the integrity of stock solutions prepared 
by different analysts and to determine if temperature and duration of storage have an influence on 
the stock solution stability. The analytes and internal standard of interest were assessed for stability 
at approximately -80°C for 69 days and at room temperature for approximately four hours. The 
percentage difference for stock solution accuracy should not be more than 5% between stock 
solutions and should not have a percentage CV above 15%. The acceptance criteria for stock solution 
stability is that the accuracy of the test solutions should be within 10% of the reference stock. Stock 
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solution accuracy and stability was tested by means of HPLC (Thermo Scientific) using the HPLC 
method described in section 4.2.1 above with UV detection at 336 nm. 
5.1.2.2 Working Solution stability  
Working solution stability was assessed at high and low concentrations to determine if there are any 
stability issues during storage at approximately -80°C or at room temperature for approximately four 
hours that may be concentration dependent. The acceptance criteria for working solution stability was 
the same as for stock solution stability described in Section 4.2 above. 
5.1.2.3 Matrix stability  
This evaluation should include at least the length of time from when the first sample was drawn during 
the clinical phase to the date of the final sample analysis during the analytical phase of a study. High 
and low QC samples were placed at -20°C and -80°C and matrix stability was determined for 
approximately 3 days. The percentage CV and accuracy should be within 15% of the nominal 
concentration. 
5.1.2.4 Fresh versus Frozen stability  
Fresh versus frozen stability was assessed by preparing a fresh set of calibration standards in 
breastmilk. These are tested against quality controls stored at approximately -80°C for 2 days. The 
fresh calibration standards are used to quantify the frozen quality controls. Accuracy and precision are 
the same as for the inter- and intra- validations described previously. 
5.1.2.5 Freeze and Thaw stability  
The freeze and thaw stability was evaluated to mimic the intended sample handling conditions to be 
used during sample analysis. Freeze-thaw stability was tested after 3 cycles. High and low QC samples 
were frozen for approximately 23 hours and thawed for approximately one hour on ice. Percentage 
difference should be within 15% of the nominal concentration and precision of the measured values 
should be less than 15%. 
5.1.2.6 Benchtop stability  
High and low QCs were frozen at approximately -80°C and placed at room temperature for 
approximately 4.5 hours on ice until extraction. These samples were analysed against a valid 
calibration curve consisting of freshly prepared standards. Percentage difference should be within 15% 
of the nominal concentration and precision of the measured values should be less than 15%. 
5.1.2.7 Reinjection reproducibility  
Reinjection reproducibility evaluation was performed to determine whether the analytical run can be 
reanalysed by reinjection in case of instrument interruptions. Reinjection reproducibility 
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demonstrates that following a batch injection and then reinjection, the results should not be 
significantly different and should not generate a significantly different calibration curve. The 
autosampler was set at approximately 8°C. Reinjection reproducibility was evaluated against the same 
calibration standards and quality controls originally injected within approximately 48 hours. The 
acceptance criteria for standards and QC’s are the same as those described for the intra- and inter-
day validation batches. 
5.1.2.8 Autosampler stability  
To evaluate autosampler stability, the same batch used for the reinjection evaluation is used to 
analyse the peak area ratios of the high and low quality control samples to compare the percentage 
difference to that of the first injection. 
5.1.3 Specificity  
The bioanalytical method is tested to determine if it is specific for the analyte of interest in the 
presence of endogenous components in the sample. Six different blank sources of breastmilk were 
extracted without an internal standard at the upper limit of quantitation (ULOQ). 
5.1.4 Sensitivity  
The bioanalytical method is tested to determine if it is sensitive enough to detect the LLOQ in the 
presence of endogenous components in the sample. Six different blank sources of breastmilk were 
spiked and extracted at LLOQ (2 ng/ml) without an internal standard. The signal-to-noise ratio for the 
analyte of interest at LLOQ should be greater than 5 times the response when compared to the 
response of the blank at the retention time of the analyte. 
5.1.5 Cross-talk 
Cross-talk must be assessed for the parent analyte, its metabolite and the respective internal standard 
used. Theoretical upper limit of quantification (ULOQ, 2000 ng/ml) and LLOQ (2 ng/ml) concentrations 
of the analyte of interest are assessed and injected in sextuplet. A peak area of less than 20% of the 
LLOQ is acceptable for the analyte of interest when injecting the ULOQ of another analyte or working 
concentration of the internal standard. To classify as cross-talk, the analytes should have the same 
retention time. 
5.1.6 Carry-over 
Carry-over is determined by the presence of an unwanted analyte signal in a blank sample following 
the injection of a sample with a high analyte concentration. Carry-over in a blank sample should be 
less than 20% of the LLOQ and less than 5% of the internal standard. 
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5.1.7 Recovery  
Recovery determines the ability of the assay to efficiently extract the analyte of interest. Recovery 
does not need to be 100% but must be consistent and reproducible. Recovery samples (extracted with 
internal standard spiked normally) are compared to blank extracted samples from 6 different matrices 
and reconstituted with injection solution containing the analytes at theoretical high, medium and low 
concentrations and the internal standard at the working concentration of the method. Quality controls 
prepared in 6 different matrices are each spiked at high, medium and low concentration levels and 
extracted. Precision (%CV) of the mean recovery should be less than 15% while the reproducibility 
within each concentration level should also be less than 15%. 
5.1.8 Matrix effects  
Matrix effects are characterized by the presence of endogenous components in a biological sample 
that may interfere with the ionization process (can either enhance or supress the ionization process). 
The Matuszewski et al. method was used as a guideline when matrix effects was tested (Matuszewski, 
et al., 1998). The strategies of Trufelli et al. and Panuwet et al. were followed to eliminate matrix 
effects, namely to ensure the appropriate extraction methods were applied to remove sample 
interferences, relevant mass spectrometry and chromatographic settings to ensure retention of the 
analytes without ion suppression or enhancement signals, using the appropriate calibration range with 
the appropriate stable isotopically labelled analogue (Trufelli, et al., 2011) (Panuwet, et al., 2016). To 
determine matrix effects blank matrix from at least six different sources are extracted without an 
internal standard (in triplicate). Each extracted matrix was then reconstituted with injection solution 
spiked at theoretical high, medium and low concentration levels. The slope variability (%CV) should 
not be more than 5% for each matrix at high, medium and low concentrations and the precision at 
each level should be less than 15%. 
5.1.9 Process efficiency  
Process efficiency compares the combined effect of instrument response and matrix effects of an 
extracted sample with the response of an unextracted sample. Quality controls prepared in 6 different 
matrices are each spiked at high, medium and low concentration levels and extracted. This was 
compared to injection solvent spiked at theoretical high, medium and low analyte concentrations. 
Process efficiency precision and the reproducibility at each concentration level should be less than 
15%. Furthermore, the mean process efficiency across the high, medium and low concentration range 
should have a precision of less than 15%. 
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6 Results and Discussion  
A bioanalytical assay is validated to ensure that it is reproducible, accurate, precise, sensitive, specific 
and determines stability of the analyte of interest during an extraction and subsequent storage 
conditions (FDA, 2018). Accuracy and precision of intra- and inter-day validation over a calibration 
range of 2 to 2000 ng/ml was evaluated over three consecutive days. A full set of working solution 
calibration standards and quality controls were prepared and frozen at approximately -80°C.  For each 
run the appropriate WS aliquots were thawed and used to spike blank breastmilk. A run consisted of 
calibration standards in duplicate and quality controls in sextuplet to obtain a calibration curve. A 
simple model for the calibration curve describing the relationship between the concentration and 
response was applied using suitable weighting and statistical tests for goodness of fit. A calibration 
curve ranging from LLOQ to ULOQ must consist of at least 6-8 calibration levels. The regression model 
(quadratic weighted by 1/x) selected for validation was used for quantifying study samples.  
The calibration curve should fit a measured plot of response against nominal concentrations of the 
calibration standards accordingly in such that an r2 fit parameter is as close to one as possible. To 
consider the method validated, intra- and inter-day percentage accuracy and precision should be 
between 85-115%, except for the LLOQ that must fall between 80-120%. Each calibration standard (in 
duplicate) should meet the stated criteria, however, only a single calibration standard is permitted to 
fail at each concentration. The failed calibration standard should be excluded from the calibration 
curve, but not any failed quality controls, and the calibration range must not be affected by the 
exclusion of either an LLOQ or ULOQ. 
6.1 Validation 1  
Intra-day accuracy and precision is determined by evaluating the calibration standards in duplicate 
and 6 quality control replicates at each level to produce one calibration curve. The assay is evaluated 
by calculating the regression equation and creating a calibration curve based on peak area ratios of 
analyte to internal standard, as displayed on the tables and figures below. 
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6.1.1 Validation 1 – rifapentine 
 
Figure 6. 1: Representative calibration curve of rifapentine - Validation 1 
The regression equation used was Quadratic (weighted 1/x concentration, f(x) = a + bx + cx2, as 
indicated in Table 6.1. Accuracy and precision results for calibration standards and quality controls are 
summarized for rifapentine Validation 1, as indicated in Table 6.2 and 6.3 respectively. 
Table 6. 1: Regression equation for rifapentine - Validation 1 
Validation Batch 
Quadratic Calibration Curve Parameters 
A b C r 
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Std Dev % CV % Accuracy n  
ng/ml ng/ml 
S11 2.00 1.93 0.0182 0.9 96.7 2 of 2 
S10 4.00 3.91 0.0416 1.1 97.6 2 of 2 
S9 8.00 8.20 0.148 1.8 102.5 2 of 2 
S8 18.0 16.8 2.04 12.2 93.2 2 of 2 
S7 35.0 35.8 1.49 4.2 102.4 2 of 2 
S6 80.0 82.9 1.24 1.5 103.6 2 of 2 
S5 180 189 7.37 3.9 105.2 2 of 2 
S4 375 377 6.46 1.7 100.7 2 of 2 
S3 750 750 32.4 4.3 100.1 2 of 2 
S2 1500 1420 31.1 2.2 94.7 2 of 2 
S1 2000 2080 155 7.4 104.0 2 of 2 
Abbreviation: Conc. – concentration; std – standard; Dev – deviation 
 







Std Dev % CV % Accuracy n 
ng/ml ng/ml 
QC LLOQ 2.00 1.94 0.113 5.8 96.9 6 of 6 
QC L 5.00 4.83 0.218 4.5 96.6 6 of 6 
QC M 800 795 27.7 3.5 99.4 6 of 6 
QC H 1600 1598 50.6 3.2 99.9 6 of 6 




6.1.2 Validation 1 – 25-O-desacetyl rifapentine 
 
Figure 6. 2: Representative calibration curve for 25-O-desacetyl rifapentine - Validation 1 
The regression equation used was Quadratic (weighted 1/x concentration, f(x) = a + bx + cx2, as 
indicated in Table 6.4. Accuracy and precision results for Calibration Standards and Quality Controls 
are summarized for 25-O-desacetyl rifapentine Validation 1, as indicated in Table 6.5 and 6.6 
respectively. 
Table 6. 4: Regression equation for 25-O-desacetyl rifapentine - Validation 1 
Validation Batch 
Quadratic Calibration Curve Parameters 
A b C r 
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Std Dev % CV % Accuracy n 
S11 2.00 1.94 0.045 2.3 97.1 2 of 2 
S10 4.00 3.59 0.190 5.3 89.7 2 of 2 
S9 8.00 8.55 0.478 5.6 106.8 2 of 2 
S8 18.0 17.0 1.71 10.1 94.7 2 of 2 
S7 35.0 37.1 3.91 10.5 106.0 2 of 2 
S6 80.0 85.4 N/A N/A 106.7 1 of 2 
S5 180 201 N/A N/A 111.5 1 of 2 
S4 375 359 18.5 5.2 95.8 2 of 2 
S3 750 770 11.6 1.5 102.7 2 of 2 
S2 1500 1439 16.3 1.1 95.9 2 of 2 
S1 2000 2045 144 7.0 102.2 2 of 2 
Abbreviation: Conc. – concentration; std - standard; Dev – deviation 
One of the standards 5 and 6 failed to meet the acceptance criteria, therefore were excluded. 







Std Dev % CV % Accuracy n 
ng/ml ng/ml 
QC LLOQ 2.00 1.98 0.186 9.4 90.1  6 of 6 
QC L 5.00 4.92 0.368 7.5 90.9 6 of 6 
QC M 800 805 72.4 9.0 96.7 6 of 6 
QC H 1600 1704 140 8.2 106.5 6 of 6 




6.2 Validation 2 
Inter-batch accuracy and precision is evaluated by assessing two separate batches consecutively. The 
calibration curve consists of duplicate calibration standards and quality controls in sextuplet. 
6.2.1 Validation 2 – rifapentine 
 
Figure 6. 3: Representative calibration curve for rifapentine - Validation 2 
This validation batch was used to evaluate stability samples against a calibration curve.  The regression 
equation used was Quadratic (weighted 1/x concentration, f(x) = a + bx + cx2, as indicated in Table 6.7. 
Accuracy and precision results for calibration standards and quality controls are summarized for 
rifapentine Validation 2, as indicated in Table 6.8 and 6.9 respectively. 
Table 6. 7: Regression equation for rifapentine Validation 2 
Validation 
Batch 
Quadratic Calibration Curve Parameters 
A b C r 
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Std Dev % CV % Accuracy n  
ng/ml ng/ml 
S11 2.00 2.13 N/A N/A 106.4 1 of 2 
S10 4.00 3.91 0.0699 1.8 97.7 2 of 2 
S9 8.00 8.02 0.133 1.7 100.3 2 of 2 
S8 18.0 17.4 0.623 3.6 96.8 2 of 2 
S7 35.0 35.6 0.188 0.5 101.6 2 of 2 
S6 80.0 78.8 5.26 6.7 98.4 2 of 2 
S5 180 184 1.70 0.9 102.0 2 of 2 
S4 375 379 34.6 9.1 101.2 2 of 2 
S3 750 739 12.9 1.8 98.5 2 of 2 
S2 1500 1505 30.8 2.1 100.3 2 of 2 
S1 2000 2001 76.3 3.8 100.0 2 of 2 
Abbreviation: Conc. – concentration; std - standard; Dev – deviation 
One of standard 11 failed to meet the acceptance criteria, therefore was excluded. 







Std Dev % CV % Accuracy n 
ng/ml ng/ml 
QC LLOQ 2.00 2.18 0.149 6.8 109.1 6 of 6 
QC L 5.00 4.90 0.111 2.3 98.0 6 of 6 
QC M 800 816 32.2 3.9 102.0 6 of 6 
QC H 1600 1606 63.9 4.0 100.3 6 of 6 




6.2.2 Validation 2 – 25-O-desacetyl rifapentine 
 
Figure 6. 4: Representative calibration curve for 25-O-desacetyl rifapentine - Validation 2 
This validation batch was used to evaluate stability samples against a fresh curve. The regression 
equation used was Quadratic (weighted 1/x concentration, f(x) = a + bx + cx2, as indicated in Table 
6.10. Accuracy and precision results for calibration standards and quality controls are summarized for 
25-O-desacetyl rifapentine Validation 2, as indicated in Table 6.11 and 6.12 respectively. 
Table 6. 10: Regression equation for 25-O-desacetyl rifapentine Validation 2 
Validation 
Batch 
Quadratic Calibration Curve Parameters 
A b C r 
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Std Dev % CV % Accuracy n  
ng/ml ng/ml 
S11 2.00 2.23 N/A N/A 111.3 1 of 2 
S10 4.00 4.00 0.433 10.8 99.9 2 of 2 
S9 8.00 7.71 0.401 5.2 96.4 2 of 2 
S8 18.0 19.4 N/A N/A 107.8 1 of 2 
S7 35.0 34.4 2.03 5.9 98.3 2 of 2 
S6 80.0 77.8 8.75 11.2 97.2 2 of 2 
S5 180 177 6.52 3.7 98.2 2 of 2 
S4 375 372 42.9 11.6 99.1 2 of 2 
S3 750 758 35.6 4.7 101.1 2 of 2 
S2 1500 1520 70.6 4.6 101.3 2 of 2 
S1 2000 1980 29.6 1.5 99.0 2 of 2 
Abbreviation: Conc. – concentration; std – standard; Dev – deviation 
One of the standards 8 and 11 failed to meet the acceptance criteria, therefore were excluded. 







Std Dev % CV % Accuracy n 
ng/ml ng/ml 
QC LLOQ 2.00 2.40 0.604 25.1 120.2 6 of 6 
QC L 5.00 4.83 0.459 9.5 96.6 6 of 6 
QC M 800 857 56.5 6.6 107.2 6 of 6 
QC H 1600 1702 90.0 5.3 106.4 6 of 6 
Abbreviation: Conc. – concentration; std - standard; Dev – deviation 
QC LLOQ failed, it yielded a percentage accuracy above the 120.0 % acceptance criteria as one of the 
QC samples failed. 
6.3 Validation 3 
Inter-batch validation is performed to assess the accuracy and precision within a batch. 
54 
 
6.3.1 Validation 3 – Rifapentine 
 
Figure 6. 5: Representative calibration curve for rifapentine - Validation 3 
The regression equation used was Quadratic (weighted 1/x concentration, f(x) = a + bx + cx2, as 
indicated in Table 6.13. Accuracy and Precision results for calibration standards and quality controls 
are summarized for rifapentine Validation 3, as indicated in Table 6.14 and 6.15 respectively. 
Table 6. 13: Regression equation for rifapentine Validation 3 
Validation 
Batch 
Quadratic Calibration Curve Parameters 
A b C r 
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Std Dev % CV % Accuracy n  
ng/ml ng/ml 
S11 2.00 2.02 0.161 8.0 100.9 2 of 2 
S10 4.00 4.11 0.227 5.5 102.8 2 of 2 
S9 8.00 8.35 0.481 5.8 104.4 2 of 2 
S8 18.0 1.1 0.383 2.1 100.7 2 of 2 
S7 35.0 33.4 1.33 4.0 95.3 2 of 2 
S6 80.0 79.2 0.593 0.7 99.0 2 of 2 
S5 180 173 8.16 4.7 96.2 2 of 2 
S4 375 371 17.3 4.7 99.0 2 of 2 
S3 750 751 29.1 3.9 100.2 2 of 2 
S2 1500 1566 18.4 1.2 104.4 2 of 2 
S1 2000 1942 110 5.6 97.1 2 of 2 
Abbreviation: Conc. – concentration; std - standard; Dev – deviation 







Std Dev % CV % Accuracy n 
ng/ml ng/ml 
QC LLOQ 2.00 1.94 0.0910 4.7 96.8 6 of 6 
QC L 5.00 4.87 0.0949 1.9 97.4 6 of 6 
QC M 800 812 20.5 2.5 101.5 6 of 6 
QC H 1600 1585 28.2 1.8 99.1 6 of 6 
Abbreviation: Conc. – concentration; std - standard; Dev – deviation 
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6.3.2 Validation 3 – 25-O-desacetyl rifapentine 
 
Figure 6. 6: Representative calibration curve for 25-O-desacetyl rifapentine -Validation day 3 
The regression equation used was Quadratic (weighted 1/x concentration, f(x) = a + bx + cx2, as 
indicated in Table 6.16. Accuracy and precision results for calibration standards and quality controls 
are summarized for 25-O-desacetyl rifapentine Validation 3, as indicated in Table 6.17 and 6.18 
respectively. 
Table 6. 16: Regression equation for 25-O-desacetyl rifapentine Validation 3 
Validation 
Batch 
Quadratic Calibration Curve Parameters 
A b C r 
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Std Dev % CV % Accuracy n  
ng/ml ng/ml 
S11 2.00 2.10 0.281 13.4 105.1 2 of 2 
S10 4.00 4.06 0.208 5.1 101.5 2 of 2 
S9 8.00 8.12 0.507 6.2 101.5 2 of 2 
S8 18.0 16.6 N/A N/A 92.2 1 of 2 
S7 35.0 34.3 1.47 4.3 98.0 2 of 2 
S6 80.0 79.2 0.853 1.1 99.0 2 of 2 
S5 180 180 5.65 3.1 99.9 2 of 2 
S4 375 361 26.3 7.3 96.1 2 of 2 
S3 750 777 25.4 3.3 103.5 2 of 2 
S2 1500 1495 81.2 5.4 99.7 2 of 2 
S1 2000 1995 37.7 1.9 99.7 2 of 2 
Abbreviation: Conc. – concentration; std - standard; Dev – deviation 
One of standard 8 failed to meet the acceptance criteria and was excluded. 








Std Dev % CV % Accuracy n 
ng/ml ng/ml 
QC LLOQ 2.00 2.17 0.180 8.3 108.7 6 of 6 
QC L 5.00 4.83 0.423 8.7 96.5 6 of 6 
QC M 800 817 61.1 7.5 102.2 6 of 6 
QC H 1600 1718 136 7.9 107.4 6 of 6 
Abbreviation: Conc. – concentration; std - standard; Dev – deviation 
6.4 Validation summary 
Complete accuracy and precision of the assay is evaluated by calculating the accuracy and precision 
statistics over inter- and intra- validation batches (3 in total). Accuracy is expressed as the percentage 
of the nominal concentration of the analyte (% Accuracy) while precision is expressed as the 
58 
 
coefficient of variation (% CV) of the analyte of interest. Summary of the combined regression, 
calibration standards and quality control results (all 3 validations) of rifapentine and 25-O-desacetyl 
rifapentine are indicated in the tables below. 
6.4.1 Validation Summary: rifapentine 
Table 6. 19: Complete summary of calibration curve parameters: Validation 1-3 - rifapentine   
Validation 
Batch 
Quadratic Calibration Curve Parameters 
A b C r 
1 -0.000000445 0.0034 0.00034 0.9992 
2 -0.000000262 0.00256 0.00031 0.9996 
3 -0.000000655 0.00495 -0.000304 0.9995 
 




1 2 3 4 5 6 7 8 9 10 11 
2000 1500 750 375 180 80.0 35.0 18.0 8.00 4.00 2.00 
ng/ml 
Replicate Observed concentration (ng/ml) 
1 
1 2190 1400 727 373 194 82.0 36.9 15.3 8.10 3.93 1.92 
2 1970 1440 773 382 184 83.8 34.8 18.2 8.31 3.88 1.95 
2 1 2050 1530 729 355 185 75.0 35.7 17.0 7.93 3.86 
No 
peak 
2 1950 1480 748 404 182 82.5 35.4 17.9 8.12 3.96 2.13 
3 
1 1860 1550 772 359 179 78.8 32.4 18.4 8.01 4.27 1.90 
2 2020 1580 731 383 167 79.6 34.3 17.9 8.69 3.95 2.13 
n 6 6 6 6 6 6 6 6 6 6 5 
Average 2007 1497 747 376 182 80.3 34.9 17.5 8.19 3.98 2.01 
STDEV 111 68.9 21.4 17.9 8.84 3.19 1.52 1.16 0.275 0.150 0.115 
% CV 5.5 4.6 2.9 4.8 4.9 4.0 4.3 6.6 3.4 3.8 5.7 
% Accuracy 100.3 99.8 99.6 100.3 101.0 100.4 99.8 96.9 102.4 99.4 100.3 
Statistics calculated using Analyst® 1.6.2 software. Italics: Failed acceptance criteria but not a statistical outlier. No peak: wrong 




Table 6. 21: Complete quality control accuracy and precision estimation: rifapentine 
Day 
Quality controls 
QC LLOQ QC Low QC Medium QC High 
2.00 5.00 800 1600 
ng/ml 
Replicate Observed concentration (ng/ml) 
1 
1 1.94 4.94 795 1660 
2 1.85 4.47 755 1600 
3 1.86 4.93 787 1560 
4 1.83 4.66 816 1580 
5 2.08 4.98 835 1530 
6 2.07 5.01 783 1650 
2 
1 2.18 4.98 817 1530 
2 2.47 4.86 857 1670 
3 2.06 4.70 837 1620 
4 2.14 4.89 815 1660 
5 2.07 4.98 810 1620 
6 2.17 4.99 761 1530 
3 
1 2.09 4.93 812 1590 
2 1.96 4.82 845 1620 
3 1.87 4.87 797 1600 
4 1.97 4.89 824 1550 
5 1.86 5.00 806 1590 
6 1.86 4.72 787 1550 
n 18 18 18 18 
Average 2.02 4.87 808 1595 
STDEV 0.164 0.145 27.3 46.8 
% CV 8.1 3.0 3.4 2.9 
% Accuracy 100.9 97.4 101.0 99.7 






6.4.2 Validation Summary: 25-O-desacetyl rifapentine 
 




Quadratic Calibration Curve Parameters 
A b C r 
1 -0.0000000718 0.00104 0.000313 0.9989 
2 -0.000000144 0.00133 -0.0000547 0.9993 
3 -0.000000163 0.00146 -0.000371 0.9995 
 




1 2 3 4 5 6 7 8 9 10 11 
2000 1500 750 375 180 80.0 35.0 18.0 8.00 4.00 2.00 
ng/ml 
Replicate Observed concentration (ng/ml) 
1 
1 1940 1430 762 372 201 [59.9] 39.9 15.8 8.88 3.72 1.91 
2 2150 1450 779 346 [225] 85.4 34.3 18.3 8.21 3.45 1.97 
2 1 2000 1470 733 341 172 71.6 33.0 [15.1] 7.42 3.69 
No 
peak 
2 1960 1570 784 402 181 84.0 35.8 19.4 7.99 4.30 2.23 
3 
1 2020 1440 794 379 184 79.8 35.3 16.6 7.76 4.21 1.90 
2 1970 1550 759 342 176 78.6 33.2 [15.1] 8.47 3.91 2.30 
n 6 6 6 6 5 5 6 4 6 6 5 
Average 2007 1485 769 364 183 79.9 35.3 17.5 8.12 3.88 2.06 
STDEV 75.8 59.9 21.9 24.8 11.2 5.42 2.53 1.6 0.519 0.326 0.189 
% CV 3.8 4.0 2.8 6.8 6.1 6.8 7.2 9.3 6.4 8.4 9.2 
% Accuracy 100.3 99.0 102.5 97.0 101.6 9599.9 100.7 97.4 101.5 97.0 103.1 
Statistics calculated using Analyst® 1.6.2 software. Italics: Failed acceptance criteria but not a statistical outlier. Data included. No peak: 
wrong concentration of the analyte added, thus did not produce a peak. STDEV: Standard deviation; STD: Standard. Bracketed concentrations 







Table 6. 24: Complete quality control accuracy and precision estimation: 25-O-desacetyl rifapentine 
Day 
Quality controls 
QC LLOQ QC Low QC Medium QC High 
2.00 5.00 800 1600 
ng/ml 
Replicate Observed concentration (ng/ml) 
1 
1 1.41 4.71 739 1790 
2 1.99 3.76 729 1730 
3 1.48 5.26 615 1500 
4 1.79 4.50 817 1810 
5 1.90 5.19 840 1560 
6 2.23 3.86 902 1840 
2 
1 1.86 4.86 825 1610 
2 3.58 4.07 796 1780 
3 2.07 4.68 884 1620 
4 2.22 5.48 932 1800 
5 2.37 5.00 902 1640 
6 2.33 4.90 804 1770 
3 
1 2.47 4.89 858 1700 
2 2.00 5.43 858 1580 
3 2.23 4.17 815 1740 
4 1.99 5.02 733 1560 
5 2.24 4.84 883 1930 
6 2.12 4.61 756 1800 
n 14 18 18 18 
Average 2.10 4.74 816 1709 
STDEV 0.180 0.503 79.1 118 
% CV 8.6 10.6 9.7 6.9 
% Accuracy 104.8 94.7 102.0 106.8 




Results from validation 1-3 above indicate that rifapentine and 25-O-desacetyl rifapentine over a 
calibration range of 2 - 2000 ng/ml were successfully validated. The LLOQ for rifapentine and 25-O-
desacetyl rifapentine was set at the concentration of the lowest validated standard, namely 2 ng/ml. 
The results indicate the method is accurate and precise over a calibration range of 2 - 2000 ng/ml 
based on analyte/internal standard peak area ratios with a quadratic calibration curve (weighting 1/x) 
for both rifapentine and 25-O-desacetyl rifapentine. Parsons et al. had a validated calibration curve 
range of 50 – 80 000 ng/ml for both rifapentine and its metabolite from dried blood spots, while the 
Dooley et al. calibration curve range was 10 – 50 000 ng/ml for rifapentine and 70 – 35 000 ng/ml for 
the metabolite from plasma (Dooley, et al., 2012) (Parsons, et al., 2014). Rezk et al. had a calibration 
curve ranging from 10 – 20 000 ng/ml for the quantitation of ARV drugs (Rezk, et al., 2007) (Rezk, et 
al., 2008). The validated calibration curve for this project covers a broad range and has a very low 
LLOQ which enables the analysis of patient samples with low rifapentine concentrations. 
6.5 Stability assessment  
Stability assessments were performed to ensure that rifapentine and 25-O-desacetyl rifapentine are 
not affected by the assay procedure or related conditions. The assay of study samples can be 
performed within the indicated criteria as established in the Tables below for both rifapentine and 25-
O-desacetyl rifapentine. 
6.5.1 Stock solution accuracy and stability  
Stock solutions SS1 for rifapentine and SS1M for 25-O-desacetyl rifapentine were prepared in 
methanol and stored at approximately -80°C for 69 days. Stability was assessed by storing an aliquot 
at room temperature (approximately 4 hours), 4°C (approximately 24 hours), -20°C (approximately 24 
hours) and compared to a reference stock stored at -80°C and a freshly prepared stock. The 
assessment was performed after 24 hours. Below are the results of rifapentine and 25-O-desacetyl 
rifapentine stock solution stability assessment. Stock solutions were tested on the spectrophotometer 










Table 6. 25: Stock solution stability of rifapentine in methanol 
 Fresh -80°C -20°C 4°C  Room temp 
Absorbance 1 0.230 0.250 0.256 0.249 0.273 
Absorbance 2 0.236 0.245 0.252 0.242 0.261 
Absorbance 3 0.241 0.235 0.246 0.244 0.259 
Average 0.236 0.243 0.251 0.245 0.264 
STDEV 0.00551 0.00764 0.0050 0.0036 0.0076 
% CV 2.3 3.1 2.0 1.5 2.9 
% Difference Ref 3.3 6.6 4.0 12.2 
% Difference -3.2 Ref 3.3 0.7 8.6 
Abbreviation: STDEV: standard deviation; Ref: reference 
Table 6. 26: Stock solution stability of 25-O-desacetyl rifapentine in methanol 
 Fresh -80°C -20°C 4°C  Room temp 
Absorbance 1 0.257 0.277 0.302 0.270 0.306 
Absorbance 2 0.264 0.283 0.306 0.307 0.307 
Absorbance 3 0.268 0.279 0.299 0.303 0.307 
Average 0.266 0.280 0.302 0.293 0.307 
STDEV 0.00283 0.00306 0.0035 0.0203 0.0006 
% CV 1.1 1.1 1.2 6.9 0.2 
% Difference Ref 5.1 13.7 10.3 15.3 
% Difference -4.9 Ref 8.1 4.9 9.7 
Abbreviation: STDEV: standard deviation; Ref: reference  
Rifapentine stock solutions were stable when stored for 69 days at approximately -80°C, and for 24 
hours at approximately -20°C and 4°C, as can be seen by comparing the absorbances at these 
conditions to the freshly prepared stock. However, rifapentine did not appear to be stable when 
stored for 4 hours on ice at room temperature when compared to the freshly prepared stock.  
However, when compared to the aliquot frozen at approximately -80°C, the sample stored at room 
temperature on ice met the criteria for stability at less than 10% difference to the reference stock. 25-
O-desacetyl rifapentine stocks were stable at approximately -80°C for 69 days. However, a relatively 
large percentage difference between the freshly prepared stock and the -80°C stock was evident and 
the remaining stability conditions do not meet the acceptance criteria when using the freshly prepared 
stock as the reference. When using the -80°C stock solution as the reference, however, the analyte 
appears to meet the criteria for stability for 4 hours at room temperature on ice and for 24 hours at 
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4°C and -20°C. To confirm these results, stability should be evaluated at room temperature for 2 to 3 
hours. Parsons and Dooley et al. prepared stock solutions in dimethyl sulfoxide (DMSO) and stored 
the stocks in the dark at -80°C until use whereas for this project stock solutions were prepared in 
methanol (Parsons, et al., 2014) (Dooley, et al., 2012). Several authors have also mentioned potential 
rifamycin instability in ambient light, storing stock solutions in the dark until use and protecting dried 
blood spots (DBS) from light using aluminium foil (Parsons, et al., 2014).    
6.5.2 Working solution stability  
Working solutions (refer to table 4.2 4 for preparation details) for rifapentine and 25-O-desacetyl 
rifapentine were prepared in methanol and water (70:30, v/v) and stored at approximately -80°C. 
Working solutions were used to spike calibration standards and quality controls at each concentration 
level in breastmilk. Stability was assessed by preparing fresh working stocks and storing aliquots of 
high and low quality controls working solutions (1 at each level) at room temperature (on ice for 
approximately 4 hours), 4°C (approximately 24 hours), -20°C (approximately 24 hours) and compared 
to a reference stock stored at -80°C by means of LC-MS/MS. Below are the results of rifapentine and 
25-O-desacetyl rifapentine working solution stability assessment. 
  
Table 6. 27: Working solution stability of rifapentine at Low concentration level 
 Fresh Low -80°C Low -20°C Low 4°C Low RT Low 
Peak Area 1 67800 61600 73600 74000 69800 
Peak Area 2 71900 60700 75000 74200 71500 
Peak Area 3 68700 60200 73800 71200 68900 
Peak Area 4 68300 59800 72500 69000 67200 
Peak Area 5 69500 61400 72000 72700 67400 
Peak Area 6 66900 59800 69100 72700 70000 
Average 68850 60583 72667 72300 69133 
STDEV 1729 786 2039 1945 1649 
% CV 2.5 1.3 2.8 2.7 2.4 
% Difference Ref -12.0 5.5 5.0 0.4 






Table 6. 28: Working solution stability of rifapentine at High concentration level 
 Fresh High -80°C High -20°C High 4°C High RT High 
Peak Area 1 21500000 22100000 21500000 24000000 16200000 
Peak Area 2 21100000 21700000 21700000 24300000 16100000 
Peak Area 3 21200000 22200000 21700000 24100000 16100000 
Peak Area 4 21400000 22100000 21600000 24400000 15800000 
Peak Area 5 21300000 22000000 21900000 24100000 16000000 
Peak Area 6 21400000 22100000 21700000 24100000 16000000 
Average 21316667 22033333 21683333 24166667 16033333 
STDEV 147196 175119 132916 150555 136626 
% CV 0.7 0.8 0.6 0.6 0.9 
% Difference Ref 3.4 1.7 13.4 -24.8 
Abbreviation: STDEV: standard deviation; Ref: reference; RT: room temperature 
 
Table 6. 29: Working solution stability of 25-O-desacetyl rifapentine at Low concentration level 
 Fresh Low -80°C Low -20°C Low 4°C Low RT Low 
Peak Area 1 15700 14100 15700 15900 16500 
Peak Area 2 16400 13000 16100 16300 14500 
Peak Area 3 16200 12400 16000 16000 14600 
Peak Area 4 16400 14100 15500 15300 14100 
Peak Area 5 16200 13100 16700 15200 14400 
Peak Area 6 16000 13000 15800 14400 15400 
Average 16150 13283 15967 15517 14917 
STDEV 266 679 418 691 889 
% CV 1.6 5.1 2.6 4.5 6.0 
% Difference Ref -17.8 -1.1 -3.9 -7.6 








Table 6. 30: Working solution stability of 25-O-desacetyl rifapentine at High concentration level 
 Fresh High -80°C High -20°C High 4°C High RT High 
Peak Area 1 5240000 5510000 5310000 6210000 3810000 
Peak Area 2 5330000 5260000 5210000 5590000 3750000 
Peak Area 3 5730000 5000000 5130000 5720000 3820000 
Peak Area 4 5400000 5140000 5250000 6120000 3540000 
Peak Area 5 5820000 5270000 5070000 5800000 3770000 
Peak Area 6 5490000 5820000 5420000 5790000 3760000 
Average 5501667 5333333 5231667 5871667 3741667 
STDEV 228859 291868 125605 240950 102648 
% CV 4.2 5.5 2.4 4.1 2.7 
% Difference Ref -3.1 -4.9 6.7 -32.0 
Abbreviation: STDEV: standard deviation; Ref: reference 
The percentage difference for stability of the working solutions should not be higher than 10%. A high 
% CV (>15%) may indicate the working solution is not stable at the representative temperature 
condition. The results of the working stock stability experiments yielded conflicting results.  
Rifapentine in the low and high working stock solutions was stable at -20°C when compared to a 
freshly prepared stock. However, at -80°C within the low WS, it resulted in a greater than 10% 
difference compared to the fresh stock. This does not correspond with the high concentration WS, 
where rifapentine was shown to be stable at -80°C. Furthermore, rifapentine in the low WS stock was 
stable at 4°C and on ice at room temperature, although within the high WS concentration, under those 
conditions it was shown to result in a greater than 10% difference compared to the fresh stock. 
Similarly, the low WS also failed for the metabolite at -80°C, suggesting that there may have been an 
on-bench error affecting the accuracy of this sample. The low WS of the metabolite was also stable at 
room temperature on-ice, at 4°C and at -20°C. Within the high WS stock, 25-O-desacetyl rifapentine 
was stable at 4°C, -20°C and -80°C, but not at room temperature on-ice. Parsons et al. and Dooley et 
al. found that the analytes were light sensitive hence the working solutions were stored in the dark 
(Dooley, et al., 2012) (Parsons, et al., 2014). The above working solution stability results indicate 
inconsistency and instability of the analytes. Parson et al. and Dooley et al. used DMSO in preparing 
the working solutions and protecting the analytes from light, however, working solution stability data 
was not shown (Dooley, et al., 2012) (Parsons, et al., 2014). The working solution stability test for this 
project failed possibly due to on-bench error rather than instability of the analytes under the tested 
conditions. This experiment should be repeated and would include room temperature stability for 
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approximately 2 hours, the maximum intended time that the working solutions would be kept at room 
temperature during spiking of breastmilk for calibration standards and QC preparation. 
6.6 Matrix stability  
This evaluation should include at least the length of time from when the first sample was drawn during 
the clinical phase to the date of the final sample analysis during the analytical phase of a study. Quality 
control samples for rifapentine and 25-O-desacetyl rifapentine were prepared in breastmilk and 
stored at approximately -80°C and -20°C for approximately 72 hours. These quality control samples 
were analysed against a freshly prepared calibration curve during validation 2 and compared to 
nominal concentrations to assess long term stability in matrix at approximately -80°C and -20°C.  
Table 6. 31: Storage stability in matrix at approximately -80°C for rifapentine 










 (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Sample 1 1600 1610 5.00 4.18 
Sample 2   1690   4.66 
Sample 3   1440   5.01 
Sample 4   1550   5.17 
Sample 5   1620   5.49 
Sample 6   1560   4.91 
 Average 1578 Average 4.90 
 STDEV 84.2 STDEV 0.449 
 % CV  5.3 % CV  9.2 
 % Difference  -1.4 % Difference  -1.9 












Table 6. 32: Storage stability in matrix at approximately -80°C for 25-O-desacetyl rifapentine 










 (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Sample 1 1600 1650 5.00 4.23 
Sample 2   1760   4.55 
Sample 3   1610   4.67 
Sample 4   1650   5.15 
Sample 5   1660   5.78 
Sample 6   1750   4.99 
 Average 1680 Average 4.90 
 STDEV 60.7 STDEV 0.542 
 % CV  3.6 % CV  11.1 
 % Difference  5.0 % Difference  -2.1 











Table 6. 33: Storage stability in matrix at approximately -20°C for rifapentine 










 (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Sample 1 1600 1690 5.00 4.77 
Sample 2   1480   4.89 
Sample 3   1540   4.89 
Sample 4   1720   4.84 
Sample 5   1590   4.91 
Sample 6   1730   4.70 
 Average 1625 Average 4.83 
 STDEV 103.7 STDEV 0.083 
 % CV  6.4 % CV  1.7 
 % Difference  1.6 % Difference  -3.3 
Abbreviation: STDEV: standard deviation 
Table 6. 34: Storage stability in matrix at approximately -20°C for 25-O-desacetyl rifapentine 










 (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Sample 1 1600 1790 5.00 5.13 
Sample 2   1510   4.83 
Sample 3   1580   4.75 
Sample 4   1810   4.77 
Sample 5   1790   5.13 
Sample 6   1840   5.03 
 Average 1720 Average 4.94 
 STDEV 139 STDEV 0.177 
 % CV  8.1 % CV  3.6 
 % Difference  7.5 % Difference  -1.2 
Abbreviation: STDEV: standard deviation 
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The precision and accuracy, as well as the percentage difference compared to the nominal 
concentration, for both rifapentine and 25-O-desacetyl rifapentine are within 15%, which indicates 
that the analytes are stable when stored at approximately -80°C and -20°C for approximately 72 hours. 
Parsons et al. reported that the different QC levels were stable in plasma samples for one day 
unprotected from light and two days when protected from light, however, samples were unstable in 
long term stability tests (data was not shown) (Parsons, et al., 2014). Further testing will be performed 
during sample analysis to establish longer term storage stability in matrix. 
6.7 Fresh versus Frozen stability  
To determine the “fresh” versus “frozen” effect, a fresh set of calibration standards are prepared in 
breastmilk and tested against stored (at approximately -80°C) QC samples. The fresh calibration 
standards are used to quantify the QC’s. 








Std Dev % CV % Accuracy n  
ng/ml ng/ml 
S11 2.00 2.13 N/A N/A 106.4 1 of 2 
S10 4.00 3.91 0.0699 1.8 97.7 2 of 2 
S9 8.00 8.02 0.133 1.7 100.3 2 of 2 
S8 18.0 17.4 0.623 3.6 96.8 2 of 2 
S7 35.0 35.6 0.188 0.5 101.6 2 of 2 
S6 80.0 78.8 5.26 6.7 98.4 2 of 2 
S5 180 184 1.70 0.9 102.0 2 of 2 
S4 375 379 34.6 9.1 101.2 2 of 2 
S3 750 739 12.9 1.8 98.5 2 of 2 
S2 1500 1505 30.8 2.1 100.3 2 of 2 
S1 2000 2001 76.3 3.8 100.0 2 of 2 














Std Dev % CV % Accuracy n 
ng/ml ng/ml 
QC LLOQ 2.00 2.18 0.149 6.8 107.4 6 of 6 
QC L 5.00 4.90 0.111 2.3 98.1 6 of 6 
QC M 800 816 32.2 3.9 100.8 6 of 6 
QC H 1600 1606 63.9 4.0 98.7 6 of 6 
Abbreviation: Std Dev: standard deviation 








Std Dev % CV % Accuracy n  
ng/ml ng/ml 
S11 2.00 2.23 N/A N/A 111.3 1 of 2 
S10 4.00 4.00 0.433 10.8 99.9 2 of 2 
S9 8.00 7.71 0.401 5.2 96.4 2 of 2 
S8 18.0 19.4 N/A N/A 107.8 1 of 2 
S7 35.0 34.4 2.03 5.9 98.3 2 of 2 
S6 80.0 77.8 8.75 11.2 97.2 2 of 2 
S5 180 177 6.52 3.7 98.2 2 of 2 
S4 375 372 42.9 11.6 99.1 2 of 2 
S3 750 758 35.6 4.7 101.1 2 of 2 
S2 1500 1520 70.6 4.6 101.3 2 of 2 
S1 2000 1980 29.6 1.5 99.0 2 of 2 















Std Dev % CV % Accuracy n 
ng/ml ng/ml 
QC LLOQ 2.00 2.40 0.604 25.1 107.4 6 of 6 
QC L 5.00 4.83 0.459 9.5 98.1 6 of 6 
QC M 800 857 56.5 6.6 100.8 6 of 6 
QC H 1600 1702 90.0 5.3 98.7 6 of 6 
Abbreviation: Std Dev: standard deviation 
The acceptance criteria for standards and QC samples are the same as for the intra- and inter-day 
validation batches. The quality controls precision and accuracy for both rifapentine and 25-O-
desacetyl rifapentine are within 15% except for QC LLOQ for 25-O-desacetyl Rifapentine that has a % 
CV of 25.1 due to two QC’s that failed. This indicates that the analyte stability is not influenced by 
sample freezing. 
6.8 Freeze and Thaw stability  
The freeze and thaw stability are evaluated to mimic the intended sample handling conditions to be 
used during sample analysis. To determine freeze-thaw stability, low and high quality controls in 
breastmilk are frozen at approximately -80°C and put through 3 consecutive freeze and thaw cycles. 
Sample aliquots were prepared and frozen for at least 24 hours prior to starting the experiment. Each 
sample was thawed sufficiently (approximately 1 hour) for each cycle at room temperature (on ice) 
followed by approximately 23 hours freezing time. The samples were analysed against a valid 
calibration curve and compared to the nominal concentrations of the high and low quality controls. 










Table 6. 39: Freeze and thaw stability of rifapentine 






Nominal QC Low 
Observed F/T 
Low 
 ng/ml ng/ml ng/ml ng/ml 
Sample 1 1600 1560 5.00 4.58 
Sample 2   1570   4.49 
Sample 3   1540   4.69 
Sample 4   1450   4.70 
Sample 5   1540   4.83 
Sample 6   1530   5.44 
 Average 1532 Average 4.79 
 STDEV 42.6 STDEV 0.339 
 % CV 2.8 % CV 7.1 
 % Difference -4.3 % Difference -4.2 
Abbreviation: Std Dev: standard deviation; F/T: freeze and thaw 
Table 6. 40: Freeze and thaw stability of 25-O-desacetyl rifapentine 






Nominal QC Low 
Observed F/T 
Low 
 ng/ml ng/ml ng/ml ng/ml 
Sample 1 1600 1770 5.00 4.95 
Sample 2   1580   5.09 
Sample 3   1720   4.44 
Sample 4   1550   5.32 
Sample 5   1670   5.07 
Sample 6   1570   5.89 
 Average 1643 Average 5.13 
 STDEV 90.3 STDEV 0.475 
 % CV 5.5 % CV 9.3 
 % Difference 2.7 % Difference 2.5 
Abbreviation: Std Dev: standard deviation; F/T: freeze and thaw 
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A high precision and percentage difference (> 15%) of the measured values may indicate freeze-thaw 
instability. The results indicated in the tables above show that rifapentine and 25-O-desacetyl 
rifapentine are stable in breastmilk for at least 3 freeze-thaw cycles. Rifapentine and its metabolite in 
human plasma were reported to be stable for approximately 29 hours at room temperature for at 
least 4 freeze-thaw cycles (UCT, 2015). Winchester et al. reported stability of the analytes for three 
freeze-thaw cycles in plasma for approximately six hours at room temperature and approximately 12 
hours at -80°C (Winchester, et al., 2015). Others have also reported at least three freeze-thaw cycles 
of rifapentine and rifampicin (Fox, et al., 2011) (Parsons, et al., 2014). 
6.9 Benchtop stability  
To determine benchtop stability, low and high quality controls were prepared and placed at room 
temperature (on ice) for approximately 4.5 hours (longer than the maximum anticipated time that 
future study samples will be left thawed until extraction). The samples were analysed against a valid 
calibration curve. The measured concentrations were compared to the nominal concentrations and 
the results are presented in Table 6.41 and 6.42. 
Table 6. 41: Benchtop stability of rifapentine for approximately 4.5 hours 
 High Concentration  Low Concentration 
 Nominal QC High 
Observed BT QC 
High 
Nominal QC Low 
Observed BT QC 
Low 
 ng/ml ng/ml ng/ml ng/ml 
Sample 1 1600 1500 5.00 4.15 
Sample 2   1580   5.14 
Sample 3   1510   5.19 
Sample 4   1570   4.01 
Sample 5   1520   4.83 
Sample 6   1670   4.81 
 Average 1558 Average 4.69 
 STDEV 64 STDEV 0.498 
 % CV 4.1 % CV 10.6 
 % Difference -2.6 % Difference -6.2 





Table 6. 42: Benchtop stability of 25-O-desacetyl rifapentine for approximately 4.5 hours 




Observed BT QC 
High 
Nominal QC Low 
Observed BT QC 
Low 
 ng/ml ng/ml ng/ml ng/ml 
Sample 1 1600 1590 5.00 4.82 
Sample 2   1550   5.27 
Sample 3   1640   5.22 
Sample 4   1680   4.71 
Sample 5   1620   5.26 
Sample 6   1920   5.50 
 Average 1667 Average 5.13 
 STDEV 132 STDEV 0.301 
 % CV 7.9 % CV 5.9 
 % Difference 4.2 % Difference 2.6 
Abbreviation: Std Dev: standard deviation; BT: benchtop 
The precision and percentage difference of rifapentine and 25-O-desacetyl rifapentine compared to 
the nominal concentrations are reported to be within 15%. Therefore, stability for both the analyte 
and metabolite in breastmilk are indicated for at least 4.5 hours at room temperature (on ice). 
Winchester et al. reported that after 24 hours there were negligible changes in the rifamycin 
concentrations when benchtop stability was investigated in ambient light conditions, but they still met 
the acceptance criteria (Winchester, et al., 2015).   
6.10 Reinjection reproducibility   
Following the injection of a validation batch consisting of duplicate calibration standards and quality 
controls in six-fold at high, medium, low and LLOQ concentrations, the extracted samples (in a 96-
microwell plate) remain in the autosampler at approximately 8°C for approximately 48 hours. The 
analytical run is reinjected in its entirety after approximately 48 hours. The reinjection reproducibility 







Table 6. 43: Calibration standards accuracy and precision – Reinjection reproducibility for rifapentine 







Std Dev % CV % Accuracy n  
ng/ml ng/ml 
S11 2.00 1.90 N/A N/A 95.1 1 of 2 
S10 4.00 4.03 0.176 4.4 100.8 2 of 2 
S9 8.00 8.27 0.115 1.4 103.3 2 of 2 
S8 18.0 17.4 1.84 10.6 96.6 2 of 2 
S7 35.0 33.9 1.12 3.3 96.9 2 of 2 
S6 80.0 80.8 0.296 0.4 101.1 2 of 2 
S5 180 187 5.69 3.0 104.0 2 of 2 
S4 375 386 2.18 0.6 103.0 2 of 2 
S3 750 721 105 14.5 96.1 2 of 2 
S2 1500 1509 26.2 1.7 100.6 2 of 2 
S1 2000 2009 179 8.9 100.4 2 of 2 
Abbreviation: Std Dev: standard deviation; Conc.: concentration 
Table 6. 44: Quality control accuracy and precision – Reinjection reproducibility for rifapentine 







Std Dev % CV % Accuracy n 
ng/ml ng/ml 
QC LLOQ 2.00 1.66 0.136 8.2 82.9 6 of 6 
QC L 5.00 4.82 0.503 10.4 96.4 6 of 6 
QC M 800 814 86.2 10.6 101.8 6 of 6 
QC H 1600 1768 97.4 5.5 110.5 6 of 6 







Table 6. 45: Calibration standards accuracy and precision – Reinjection reproducibility for 25-O-







Std Dev % CV % Accuracy n  
ng/ml ng/ml 
S11 2.00 1.85 0.0974 5.3 92.5 2 of 2 
S10 4.00 3.72 N/A N/A 92.9 1 of 2 
S9 8.00 8.40 0.478 5.7 105.0 2 of 2 
S8 18.0 17.9 0.967 5.4 99.6 2 of 2 
S7 35.0 34.3 1.49 4.3 97.9 2 of 2 
S6 80.0 81.4 11.3 13.8 101.8 2 of 2 
S5 180 196 7.89 4.0 108.8 2 of 2 
S4 375 375 18.2 4.9 100.1 2 of 2 
S3 750 751 0.609 0.1 100.2 2 of 2 
S2 1500 1414 63.4 4.5 94.3 2 of 2 
S1 2000 2073 60.4 2.9 103.7 2 of 2 
Abbreviation: Std Dev: standard deviation; Conc.: concentration 
Table 6. 46: Quality control accuracy and precision – Reinjection reproducibility for 25-O-desacetyl 







Std Dev % CV % Accuracy n 
ng/ml ng/ml 
QC LLOQ 2.00 1.98 0.134 6.7 99.0 6 of 6 
QC L 5.00 4.84 0.786 16.2 96.8 6 of 6 
QC M 800 797 48.7 6.1 99.6 6 of 6 
QC H 1600 1857 97.1 5.2 116.1 6 of 6 
Abbreviation: Std Dev: standard deviation; Conc.: concentration 
The precision and accuracy of the standards and QC’s for rifapentine and 25-O-desacetyl rifapentine 
are reported to be within 15 % except for one QC High failure that resulted in a percentage accuracy 
of 116.1% and one QC Low failure with a percentage accuracy of 16.2%. The QCs still meet the criteria 
as 50% at each QC level passed and 67% of the total QCs in the batch passed. This indicates that an 
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entire batch may be injected within approximately 48 hours with the autosampler set at 
approximately 8°C. Reinjection stability will also be tested in future after 24 hours on-instrument. 
6.11 Autosampler stability  
To evaluate autosampler stability the same batch used for the reinjection evaluation after 
approximately 48 hours on-instrument (reinjection reproducibility), was used to analyse peak area 
ratios of the high and low QC samples to assess the percentage difference when compared to the first 
injection (Validation 1). This offers an estimation of absolute autosampler stability over approximately 
48 hours, to determine whether the batch may be partially reinjected or should be restarted in its 





















Table 6. 47: Autosampler stability for extracted samples: High concentration for rifapentine 
High Concentration  
Validation 1, Batch 
Start 
Peak area ISTD peak area Ratio 
Injection 1 34000000 7700000 4.42 
Injection 2 32800000 7630000 4.30 
Injection 3 33300000 7890000 4.22 
Injection 4 34200000 8040000 4.25 
Injection 5 33300000 8010000 4.16 
Injection 6 34700000 7900000 4.39 
Average 33716667 7861667 4.29 
STDEV 702614 164853 0.100 
% CV 2.1 2.1 2.3 
Validation 1 Re-
injection End 
Peak area ISTD peak area Ratio 
Injection 7 27200000 7420000 3.67 
Injection 8 26300000 7290000 3.61 
Injection 9 24200000 7330000 3.30 
Injection 10 26800000 7390000 3.63 
Injection 11 27200000 7460000 3.65 
Injection 12 27100000 7290000 3.72 
Average 26466667 7363333 3.59 
STDEV 1162182 70899 0.148 
% CV 4.4 1.0 4.1 
% Difference after Validation 1 Re-injection -16.2 









Table 6. 48: Autosampler stability for extracted samples: Low concentration for rifapentine 
Low Concentration  
Validation 1, Batch 
Start 
Peak area ISTD peak area Ratio 
Injection 1 130000 7590000 0.0171 
Injection 2 114000 7370000 0.0155 
Injection 3 127000 7460000 0.0170 
Injection 4 120000 7440000 0.0161 
Injection 5 130000 7540000 0.0172 
Injection 6 131000 7540000 0.0174 
Average 125333 7490000 0.0167 
STDEV 6861 80994 0.000758 
% CV 5.5 1.1 4.5 
Validation 1 Re-
injection 
Peak area ISTD peak area Ratio 
Injection 7 102000 7430000 0.0137 
Injection 8 83600 7240000 0.0115 
Injection 9 94600 7280000 0.0130 
Injection 10 92200 7040000 0.0131 
Injection 11 106000 7120000 0.0149 
Injection 12 105000 6960000 0.0151 
Average 97233 7178333 0.0136 
STDEV 8695 171862 0.00132 
% CV 8.9 2.4 9.7 
% Difference after Validation 1 Re-injection -19.0 









Table 6. 49: Autosampler stability for extracted samples: High concentration for 25-O-desacetyl 
rifapentine 
High Concentration  
Validation 1, Batch 
Start 
Peak area ISTD peak area Ratio 
Injection 1 12500000 7700000 1.62 
Injection 2 12000000 7630000 1.57 
Injection 3 11000000 7890000 1.39 
Injection 4 13200000 8040000 1.64 
Injection 5 11500000 8010000 1.44 
Injection 6 13100000 7900000 1.66 
Average 12216667 7861667 1.55 
STDEV 879583 164853 0.112 
% CV 7.2 2.1 7.2 
Validation 1 Re-
injection End 
Peak area ISTD peak area Ratio 
Injection 7 9520000 7420000 1.28 
Injection 8 9280000 7290000 1.27 
Injection 9 9050000 7330000 1.23 
Injection 10 10200000 7390000 1.38 
Injection 11 9320000 7460000 1.25 
Injection 12 9650000 7290000 1.32 
Average 9503333 7363333 1.29 
STDEV 399032 70899 0.0535 
% CV 4.2 1.0 4.1 
% Difference after Validation 1 Re-injection -17.0 








Table 6. 50: Autosampler stability for extracted samples: Low concentration for 25-O-desacetyl 
rifapentine 
Low Concentration  
Validation 1, Batch 
Start 
Peak area ISTD peak area Ratio 
Injection 1 39400 7590000 0.00519 
Injection 2 31000 7370000 0.00421 
Injection 3 43000 7460000 0.00576 
Injection 4 37000 7440000 0.00497 
Injection 5 42900 7540000 0.00569 
Injection 6 32500 7540000 0.00431 
Average 37633 7490000 0.00502 
STDEV 5107 80994 0.000663 
% CV 13.6 1.1 13.2 
Validation 1 Re-
injection 
Peak area ISTD peak area Ratio 
Injection 7 38300 7430000 0.00515 
Injection 8 26000 7240000 0.00359 
Injection 9 29300 7280000 0.00402 
Injection 10 25100 7040000 0.00357 
Injection 11 34200 7120000 0.00480 
Injection 12 31800 6960000 0.00457 
Average 30783 7178333 0.00428 
STDEV 5032 171862 0.000659 
% CV 16.3 2.4 15.4 
% Difference after Validation 1 Re-injection -14.7 
Abbreviation: ISTD: internal standard; STDEV: standard deviation 
The tables above indicate that for the high and low QC sample peak area ratios of rifapentine, the 
percentage difference between the first and second injections are greater than 15% with values of -
16.2 and -19% respectively. Similarly, the ratios for the high concentration of the metabolite show a 
similar trend with a value of -17%. Although the low concentration of the metabolite percentage 
difference is less than 15%, it is very close to the cut-off criteria, with a value of -14.7%. It appears that 
even with the addition of ascorbic acid to the injection solvent, rifapentine and its metabolite still 
degrade over time on-instrument, as indicated by the decrease in peak areas of the analytes and 
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internal standard, leading to a decrease in the ratio. This shows that a partial batch cannot be 
reinjected after 48 hours on-instrument at approximately 8°C, and that the batch should alternatively 
be reinjected in its entirety. Dooley et al. used foil to cover the autosampler and protect samples from 
light, which could have helped in providing stability of the analytes (Dooley, et al., 2012).  
6.12 Specificity  
Very high specificity of LC-MS/MS precludes the detection of any analytes that do not possess the 
capability to produce the specific parent ion followed by formation of the specific product ion 
produced and monitored in the mass spectrometer. Representative chromatograms of rifapentine and 
25-O-desacetyl rifapentine ULOQ are presented in Figures 6.7 to 6.8. 
 
Figure 6. 7: Representative chromatogram of ULOQ at 2000 ng/ml for rifapentine 
Sample Name: "ULOQ RPT_01"    Sample ID: ""    File: "1037.wiff"
Peak Name: "RPT_1"    Mass(es): "877.525/845.600 Da"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc: No Intercept           
Acq. Date:       2018/09/24  
Acq. Time:       03:53:30 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:   20.00   cps
Area Threshold:  200.00   cps
,Num. Smooths:       3     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        2.81   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     2.68   min
Area:         22200000.   counts
Height:         3.09e+006  cps
Start Time:         2.36   min
End Time:           3.65   min








































Sample Name: "ULOQ RPT_01"    Sample ID: ""    File: "1037.wiff"
Peak Name: "Rif-d3_1(IS)"    Mass(es): "827.415/795.600 Da"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       2018/09/24  
Acq. Time:       03:53:30 PM  
 
Modified:           No    





























































Figure 6. 8: Representative chromatogram of ULOQ at 2000 ng/ml for 25-O-desacetyl rifapentine 
The chromatograms above indicate that the method is specific for rifapentine and its metabolite with 
no interfering peaks. This corresponded with literature reports of methods specific for the rifamycins 
(Fox, et al., 2011) (Winchester, et al., 2015). 
6.13 Sensitivity  
The LLOQ of this method is 2 ng/ml. Representative chromatograms of the LLOQ for both rifapentine 
and 25-O-desacetyl rifapentine including signal to noise (S/N) ratios are presented in Figure 6.9. 
Sample Name: "ULOQ dRPT_01"    Sample ID: ""    File: "1030.wiff"
Peak Name: "DesRPT_1"    Mass(es): "835.430/803.500 Da"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc: No Intercept           
Acq. Date:       2018/09/24  
Acq. Time:       03:18:42 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:   50.00   cps
Area Threshold:  200.00   cps
,Num. Smooths:       3     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.96   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     1.86   min
Area:         9010000.   counts
Height:         1.51e+006  cps
Start Time:         1.68   min
End Time:           2.44   min







































Sample Name: "ULOQ dRPT_01"    Sample ID: ""    File: "1030.wiff"
Peak Name: "Rif-d3_1(IS)"    Mass(es): "827.415/795.600 Da"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       2018/09/24  
Acq. Time:       03:18:42 PM  
 
Modified:           No    



































































Figure 6. 9: Chromatogram of the S/N ratio for rifapentine and 25-O-desacetyl rifapentine, 
respectively: LLOQ at 2 ng/ml 
The signal-to-noise ratio for the analyte of interest at LLOQ should be greater than 5 times the 
response when compared to the response of the blank at the retention time of the analyte. Interfering 
peaks at the retention time of interest should be < 20% of the LLOQ and should not be > 5% of the 
internal standard mean response. The above representative chromatograms for rifapentine and 25-
O-desacetyl rifapentine at LLOQ of 2 ng/ml, show acceptable intensities with the signal to noise ratios 
of 58.4 and 14.9 rifapentine and 25-O-desacetyl rifapentine, respectively.  
6.14 Cross-talk 
Cross-talk must be assessed for the respective analyte, its metabolite and the internal standard used. 
ULOQ and LLOQ concentrations of rifapentine, 25-O-desacetyl rifapentine and rifampicin-d3 were 
assessed and injected at least 6 times (Matuszewski, et al., 1998).  






XIC of +MRM (9 pairs): 87.525/845.60 Da ID: RPT_1 from Sample 1 (Sensitivity LOQ 2 _ 01) of 1017.wif (Turbo Spray), Smothed Max. 2564.7 cps.













! !- Noise -
S/N = 58.4
Peak Int.(Subt.)=2.5e+3
Ymax=4.4e+1 cps Ymin=1.1e-1 cps
XIC of +MRM (9 pairs): 835.430/803.50 Da ID: DesRPT_1 from Sample 1 (Sensitivity LOQ 2 _ 01) of 1017.wif (Turbo Spray), Smothed Max. 858.4 cps.

















3.02-2.41 -1.63 -0.75 -0.45 ! !- Noise -
S/N = 14.9
Peak Int.(Subt.)=7.9e+2
Ymax=5.4e+1 cps Ymin=8.4e-1 cps
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Table 6. 51: Cross-talk peak areas for rifapentine and 25-O-desacetyl rifapentine 
  
Average analyte peak areas 
 
 
Injection Rifapentine 25-O-desacetyl rifapentine Rifampicin-d3 
Rifapentine LLOQ 58567 0 0 
Rifapentine ULLOQ 21733333 0 0 
25-desRifapentine LLOQ 0 25650 0 
25-desRifapentine ULLOQ 1001 9111667 0 
Rifampicin-d3 0 0 10340000 
* Cross-talk calculation: (1001/58567) *100 = 1.71%  
A peak area of less than 20% is acceptable for the analyte of interest when the ULOQ of the other 
analyte or internal standard is injected. In this method, no cross-talk was observed between 
rifapentine, 25-O-desacetyl rifapentine and rifampicin-d3 (internal standard).  
6.15 Carry-over 
A double blank sample (without analyte and internal standard) was positioned in the injection 
sequence immediately after the highest calibration standard in order to evaluate the possibility of 
carry-over effects. Chromatograms of double blank samples are presented in Figures 6.10 and 6.11. 
 
Figure 6. 10: Chromatogram of a double blank breastmilk sample – rifapentine 
Sample Name: "DB"    Sample ID: ""    File: "1002.wiff"
Peak Name: "RPT_1"    Mass(es): "877.525/845.600 Da"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Double Blank  
Concentration:      0.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       2018/10/03  
Acq. Time:       08:39:39 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:   20.00   cps
Area Threshold:  200.00   cps
,Num. Smooths:       3     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        2.66   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     2.66   min
Area:           1360.   counts
Height:         1.72e+002  cps
Start Time:         2.55   min
End Time:           2.79   min

















































Sample Name: "DB"    Sample ID: ""    File: "1002.wiff"
Peak Name: "Rif-d3_1(IS)"    Mass(es): "827.415/795.600 Da"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Double Blank  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       2018/10/03  
Acq. Time:       08:39:39 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:   50.00   cps
Area Threshold:  200.00   cps
,Num. Smooths:       3     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.94   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     1.94   min
Area:            779.   counts
Height:         2.08e+002  cps
Start Time:         1.85   min
End Time:           2.00   min




























































Figure 6. 11: Chromatogram of a double blank breastmilk sample - 25-O-desacetyl rifapentine 
A blank sample (without analyte) was also included to determine the possibility of contamination of 
the analyte by the internal standard without an additional carry-over effect. Chromatograms of blank 
samples are presented in Figures 6.12 and 6.13. 
 
Figure 6. 12: Chromatogram of a blank breastmilk sample - rifapentine 
Sample Name: "DB"    Sample ID: ""    File: "1002.wiff"
Peak Name: "DesRPT_1"    Mass(es): "835.430/803.500 Da"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Double Blank  
Concentration:      0.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       2018/10/03  
Acq. Time:       08:39:39 PM  
 
Modified:           No    



































2.340.42 0.56 2.851.02 2.752.211.12 1.48
3.04 3.901.71 3.74
Sample Name: "DB"    Sample ID: ""    File: "1002.wiff"
Peak Name: "Rif-d3_1(IS)"    Mass(es): "827.415/795.600 Da"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Double Blank  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       2018/10/03  
Acq. Time:       08:39:39 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:   50.00   cps
Area Threshold:  200.00   cps
,Num. Smooths:       3     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.94   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     1.94   min
Area:            779.   counts
Height:         2.08e+002  cps
Start Time:         1.85   min
End Time:           2.00   min
























































2.771.62 2.54 2.862.18 3.433.34 3.58
Sample Name: "B"    Sample ID: ""    File: "1003.wiff"
Peak Name: "RPT_1"    Mass(es): "877.525/845.600 Da"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:       Blank  
Concentration:      0.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       2018/10/14  
Acq. Time:       09:19:19 PM  
 
Modified:           No    






























































Sample Name: "B"    Sample ID: ""    File: "1003.wiff"
Peak Name: "Rif-d3_1(IS)"    Mass(es): "827.415/795.600 Da"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:       Blank  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       2018/10/14  
Acq. Time:       09:19:19 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:   50.00   cps
Area Threshold:  200.00   cps
,Num. Smooths:       3     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.94   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     1.94   min
Area:         5310000.   counts
Height:         9.26e+005  cps
Start Time:         1.71   min
End Time:           2.44   min



























































Figure 6. 13: Chromatogram of a blank breastmilk sample - 25-O-desacetyl rifapentine 
An observed analyte peak in the double blank should be less than 20% of the peak area obtained at 
the LLOQ. An observed internal standard peak should not be above 5% of the peak observed for the 
internal standard at the working concentration. 
An observed analyte peak when internal standard is present at the working concentration should not 
be greater than 20% of the peak area obtained at the LLOQ. The chromatograms shown above indicate 
that no significant carryover or contamination was observed in the double blank or blank samples for 
rifapentine and 25-O-desacetyl rifapentine. 
6.16 Recovery  
Extraction recovery relates to the extraction efficiency of the analytical process within limits of 
variability. It is determined by comparing the analytical response of blank matrix spiked with 
rifapentine and 25-O-desacetyl rifapentine and extracted with the response of the blank matrix first 
extracted and then spiked with rifapentine and 25-O-desaectyl rifapentine (theoretical, represents 
100% recovery). No recovery of the internal standard is calculated. For the extracted test samples, six 
quality controls at each concentration level (low, medium and high) are extracted as per analytical 
method from six different sources of matrix. For the theoretical samples, blank matrix from six 
different sources are extracted and the samples are reconstituted in injection solvent spiked at 
theoretical high, medium and low concentrations. 
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Peak areas observed after extraction are compared to the theoretical peak areas and expressed as 
percentage recovery. Tables 6.52 and 6.53 present recovery results for rifapentine and 25-O-desacetyl 
rifapentine. 
Table 6. 52: Recovery of rifapentine  
 
High Concentration  
(1600 ng/ml) 
Medium Concentration  
(800 ng/ml) 
Low Concentration  
(5.00 ng/ml) 
Recovery  Theoretical   Recovery  Theoretical  Recovery  Theoretical  
Peak Area Peak Area Peak Area Peak Area Peak Area Peak Area 
Sample 1 24100000 31600000 13400000 16400000 93500 103000 
Sample 2 22800000 28700000 11700000 15300000 102000 101000 
Sample 3 24900000 27800000 13800000 15500000 87000 100000 
Sample 4 24500000 27200000 13700000 15300000 88100 102000 
Sample 5 22600000 28000000 12900000 14400000 74300 116000 
Sample 6 24800000 27500000 13900000 15700000 83800 116000 
Average 23950000 28466667 13233333 15433333 88117 106333 
STDEV 1009455 1616993 833467 650128 9301 7554 
% CV 4.2 5.7 6.3 4.2 10.6 7.1 
% 
Recovery 
  84.1   85.7   82.9 
     Average % Recovery 84.2 
    















Table 6. 53: Recovery of 25-O-desacetyl rifapentine  
 




Low Concentration  
(5.0 ng/ml) 
Recovery  Theoretical  Recovery Theoretical  Recovery  Theoretical  
Peak Area Peak Area Peak Area Peak Area Peak Area Peak Area 
Sample 1 7470000 11300000 3500000 5310000 40400 *[30500]  
Sample 2 5530000 9620000 3070000 4360000 44800 39700 
Sample 3 7070000 8100000 3650000 4580000 42600 43900 
Sample 4 6890000 8270000 3870000 4580000 37700 41400 
Sample 5 6000000 9360000 3730000 4400000 28800 45700 
Sample 6 6390000 9800000 3560000 5070000 42100 58000 
Average 6558333 9408333 3563333 4716667 39400 45740 
STDEV 721177 1165031 274493 385158 5709 7229 
% CV 11.0 12.4 7.7 8.2 14.5 15.8 
% 
Recovery 
  69.7   75.5   86.1 
     Average % Recovery 77.1 
    
Average % CV 10.8 
*Statistical Outlier 
The mean recovery of a quantitative drug assay method is required to be consistent and the precision 
of the measured recovery expressed as percentage coefficient of variation should not be greater than 
15% for any concentration of the analyte that is determined. Recovery reproducibility between 
concentration levels should not be greater than 15%. 
The mean recovery of rifapentine and 25-O-desacetyl rifapentine from breastmilk over the calibration 
range is 84.2 % with a CV (%) of 1.7 and 77.1 % with a CV (%) of 10.8, respectively. The mean recovery 
was within acceptable limits. For the metabolite, the precision at the low concentration for the 
theoretical sample is 15.8%, above the acceptance criteria of 15%.  Furthermore, one sample has been 
excluded as an outlier. This experiment should be repeated to obtain better consistency for the sample 
subset. Previous publications have shown recovery of both rifapentine and its metabolite to be higher 
in plasma compared to whole blood DBS. The recovery of both rifapentine and its metabolite ranged 
from 94-98% and 96-100% in plasma, respectively (Parsons, et al., 2014). Whole blood DBS recovery 
of rifapentine and its metabolite ranged from 42-64% and 56-70%, respectively (Parsons, et al., 2014). 
Recovery of rifapentine and its metabolite in human plasma was above 86% with protein precipitation 
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(Winchester, et al., 2015), whereas in the current project the combination of both protein 
precipitation and SPE enabled high recovery of analytes from breastmilk.  
6.17 Matrix effects 
Matrix effects relates to the presence of endogenous components in a biological sample being studied. 
Matrix effects are important in LC-MS/MS analysis and may become evident once unknown clinical 
samples are analysed. The presence of endogenous components may affect ionization of an analyte 
or internal standard. Having an appropriate internal standard that adequately follows the analyte path 
can, in some instances, minimise the effect of endogenous matrix components. Appropriate steps 
should be taken to minimize the influence of endogenous matrix components. The Matuszewski 
method attempts to quantify the effect across the calibration range of the assay using different matrix 
sources (Matuszewski, et al., 1998). Six different blank sources of breastmilk were extracted (without 
internal standard). Each individual extracted matrix sample was reconstituted in injection solvent 
spiked at high, medium and low concentrations (any calculations for dilutions were considered) and 
one at one concentration of the internal standard. It is recommended that a stable isotopically labelled 
internal standard is used in quantitative assays (Matuszewski, et al., 1998). Disadvantages of using a 
stable isotopically labelled internal standard includes inadequate isotopic purity and in some cases the 
lack of sufficient stability of the isotopically labelled internal standard which leads to contamination 
of an unlabelled material and isotopic exchange during extraction (Matuszewski, et al., 1998). Dooley 
et al. used rifampicin-d3 as an internal standard due to unavailability of a stable isotopically labelled 
analogue for rifapentine and its metabolite, for this project rifampicin-d3 was also used as an internal 
standard due to unavailability of a stable isotopically labelled analogue (Dooley, et al., 2012). The 
acceptance criteria for the regression slope determined using an isotopically labelled analogue of the 
analyte as internal standard should not be more than 5%, while when using a non-isotopically labelled 
analogue of the analyte the acceptance criteria for the regression slope should not be more than 10%.  
Matrix effects results are presented in Table 6.54 and 6.55 and the overall % CV of the regression 









Table 6. 54: Matrix effect for rifapentine extracted from breastmilk   
Table A: The peak areas for the analyte and internal standard at high, medium and low concentrations  
 High Concentration  Medium Concentration  Low Concentration  
 
Analyte 








Peak Area  
ISTD Peak 
Area  
Matrix 1 31600000 4150000 16400000 3700000 103000 3530000 
Matrix 2 28700000 3930000 15300000 3350000 105000 3770000 
Matrix 3 27800000 3800000 15500000 3440000 116000 3760000 
Matrix 4 27200000 3670000 15300000 3520000 112000 3750000 
Matrix 5 28000000 3780000 14400000 3420000 115000 4140000 
Matrix 6 27500000 3600000 15700000 3540000 122000 4250000 
 
Table B: The peak area ratios and subsequent regression slope for each matrix 
 High Conc.  Medium Conc.  Low Conc.  Area Ratio  
 1600 ng/ml 800 ng/ml 5.00 ng/ml v Conc.  
 Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
Matrix 1 7.61 4.43 0.0292 0.00475 
Matrix 2 7.30 4.57 0.0279 0.00456 
Matrix 3 7.32 4.51 0.0309 0.00457 
Matrix 4 7.41 4.35 0.0299 0.00463 
Matrix 5 7.41 4.21 0.0278 0.00463 
Matrix 6 7.64 4.44 0.0287 0.00477 
Average 7.45 4.42 0.0290 0.00465 
STDEV 0.145 0.125 0.00119 0.0000914 









Table 6. 55: Matrix effect for 25-O-desacetyl rifapentine extracted from breastmilk   
Table A: The peak areas for the analyte and internal standard at high, medium and low concentrations  
 High Concentration  Medium Concentration  Low Concentration  
 
Analyte 








Peak Area  
ISTD Peak 
Area  
Matrix 1 11300000 4150000 5310000 3700000 22200 3530000 
Matrix 2 9620000 3930000 4360000 3350000 29500 3770000 
Matrix 3 8100000 3800000 4580000 3440000 27400 3760000 
Matrix 4 8270000 3670000 4580000 3520000 27500 3750000 
Matrix 5 9360000 3780000 4400000 3420000 31000 4140000 
Matrix 6 9800000 3600000 5070000 3540000 29800 4250000 
 
Table B: The peak area ratios and subsequent regression slope for each matrix 
 High Conc.  Medium Conc.  Low Conc.  Area Ratio  
 1600 ng/ml 800 ng/ml 5.00 ng/ml v Conc.  
 Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
Matrix 1 2.72 1.44 0.00629 0.00170 
Matrix 2 2.45 1.30 0.00782 0.00153 
Matrix 3 2.13 1.33 0.00729 0.00133 
Matrix 4 2.25 1.30 0.00733 0.00141 
Matrix 5 2.48 1.29 0.00749 0.00155 
Matrix 6 2.72 1.43 0.00701 0.00170 
Average 2.46 1.35 0.00721 0.00154 
STDEV 0.240 0.0680 0.000522 0.000151 
% CV 9.8 5.0 7.2 9.8 
 
High precision of the measured values may indicate a matrix effect across the 6 different matrix 
sources. For methods not utilizing stable isotopically labelled analogues of the analytes as internal 
standards, the acceptance criteria for the regression slope is that the precision across 6 different 
matrices should be less than 10%. Parsons et al. reported matrix effects to be higher in plasma 
compared to whole blood DBS (Parsons, et al., 2014). The matrix factor for whole blood DBS of 
rifapentine and its metabolite ranged from 77-90% and 78-92%, respectively (Parsons, et al., 2014). 
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Plasma matrix factor of rifapentine and its metabolite ranged from 92-99% and 92-101%, respectively 
(Parsons, et al., 2014). The precision of the regression slope for rifapentine and 25-O-desacetyl 
rifapentine are reported to be within 10 % in this study, indicating that matrix effects do not adversely 
influence the precision and accuracy of the assay. 
6.18 Process efficiency  
Process efficiency is determined by comparing the instrument response of an extracted sample with 
the response of an unextracted sample. Quality controls from six different matrix sources are each 
spiked at high, medium and low analyte concentrations. These are compared to injection solvent 
spiked at the theoretical high, medium and low analyte concentrations. Process efficiency precision 
and the reproducibility at each concentration level should not be greater than 15%. 
Table 6. 56: Process efficiency of rifapentine   
 
High Concentration  
1600 ng/ml 
Medium Concentration  
800 ng/ml 











Peak Area Peak Area Peak Area Peak Area Peak Area Peak Area 
Sample 1 24100000 27000000 13400000 14400000 93500 115000 
Sample 2 22800000 31100000 11700000 15000000 102000 113000 
Sample 3 24900000 30900000 13800000 15700000 87000 117000 
Sample 4 24500000 30400000 13700000 15300000 88100 111000 
Sample 5 22600000 32100000 12900000 16800000 74300 113000 
Sample 6 24800000 30200000 13900000 16500000 83800 113000 
Average 23950000 30283333 13233333 15616667 88117 113667 
STDEV 1009455 1740594 833467 910860 9301 2066 
% CV 4.2 5.7 6.3 5.8 10.6 1.8 
% PE   79.1   84.7   77.5 
     Average % PE 80.4 
    







Table 6. 57: Process efficiency of 25-O-desacetyl rifapentine  
Table A: The analyte and internal standards at the high, medium and low concentrations  
 
 




















7470000 7510000 3500000 8390000 40400 7210000 
5530000 6800000 3070000 6210000 44800 7620000 
7060000 7640000 3650000 7620000 42600 7610000 
6890000 8090000 3870000 7550000 37700 6050000 
6000000 7110000 3720000 7220000 28800 5370000 
6390000 7370000 3560000 7180000 42100 7540000 
 
Analyte 













8250000 9430000 3760000 7920000 51700 7410000 
11600000 10900000 3870000 8800000 34400 5920000 
9600000 11000000 4270000 9450000 37000 5980000 
11100000 11400000 4220000 9310000 32100 5530000 
11900000 11400000 5440000 10100000 33300 5580000 












Table B: The analyte to peak area ratios 
 
Process efficiency evaluates the combined contribution of matrix effects and instrument response to 
the robustness of the method. The mean process efficiency of rifapentine and 25-O-desacetyl 
rifapentine from breastmilk over the tested range is 80.4% with a CV (%) of 4.7 and 95.7% with a CV 
(%) of 5.7, respectively. Instrument drift was noted over the duration of analysis, therefore, for 25-O-
desacetyl rifapentine the analyte to internal standard ratio was used to compensate for any variation. 
The mean process efficiency was within acceptable limits. Parsons et al. reported high process 
efficiency in plasma compared to whole blood DBS (Parsons, et al., 2014). Plasma process efficiency 
ranged from 91-93% and 92-97% for Rifapentine and its metabolite, respectively (Parsons, et al., 
2014). Process efficiency in whole blood DBS ranged from 33-58% and 44-65% for rifapentine and its 
metabolite, respectively (Parsons, et al., 2014).   
 
High Concentration  
1600 ng/ml 
Medium Concentration  
800 ng/ml 
Low Concentration  
5.00 ng/ml 























Sample 1 0.995 0.875 0.417 0.475 0.00560 0.00698 
Sample 2 0.813 1.06 0.494 0.440 0.00588 0.00581 
Sample 3 0.924 0.873 0.479 0.452 0.00560 0.00619 
Sample 4 0.852 0.974 0.513 0.453 0.00623 0.00580 
Sample 5 0.844 1.04 0.515 0.539 0.00536 0.00597 
Sample 6 0.867 0.955 0.496 0.501 0.00558 0.00581 
Average 0.882 0.964 0.486 0.477 0.00571 0.00609 
STDEV 0.0660 0.0811 0.0361 0.0373 0.000304 0.000458 
% CV 7.5 8.4 7.4 7.8 5.3 7.5 
% PE   91.5   101.9   93.7 
 
   




   





7 Conclusion and Future work 
Several extraction methods were evaluated, but persistent residual fatty components within the 
sample resulted in matrix effects, as observed by Rezk et al. (Rezk, et al., 2007) (Rezk, et al., 2008). 
The finalized method combining protein precipitation and solid phase extraction enabled extensive 
sample clean-up to remove fatty components and have acceptable matrix effects. Overall matrix 
effects from six different sources of human breastmilk for both rifapentine and its metabolite was 
2.0% and 9.8%, respectively. 
Addition of ascorbic acid enabled the stability of rifapentine and its metabolite during extraction, 
which was similar to that observed by Parsons et al. and Winchester et al. (Parsons, et al., 2014) 
(Winchester, et al., 2015). 
Rifapentine mean extraction yield was 84.2% (%CV = 1.7) and that of 25-O-desacetyl rifapentine was 
71.1% (%CV = 10.8), however, precision for the metabolite at QC low does not meet the acceptance 
criteria, therefore, this experiment should be repeated in future work. The extraction method using 
100 µl of breastmilk and protein precipitation followed by solid phase extraction results in good 
recovery of the analytes. Rifapentine had a mean process efficiency of 80.4% (%CV = 4.7) and that of 
25-O-desacetyl rifapentine was 95.7% (%CV = 5.7), indicating that the method is robust. 
The finalized extraction method was validated according to FDA guidelines on an API 4000 using an 
Agilent Poroshell 120 EC-C18 (4.6 x 50 mm, 2.7 μm) for chromatographic separation with an isocratic 
method of acetonitrile containing 0.1% formic acid and water containing 10% methanol and 0.1% 
formic acid  (55:45, v/v) and a flowrate of 450 µl/ml. Rifampicin-d3 was used as an internal standard 
due to the unavailability of a stable isotopically labelled analogue of the analytes, as has similarly been 
reported by Bao et al. (Bao, et al., 2008). 
Intra- and inter- day validations over 3 days were successfully performed. The calibration curves fit a 
quadratic regression with 1/x weighting over a concentration range of 2 - 2000 ng/ml for both 
rifapentine and 25-O-desacetyl rifapentine based on the analyte/internal standard peak area ratios. 
The broad calibration range chosen using free fraction information as a guideline for rifapentine and 
25-O-desacetyl rifapentine was validated as there is no information on the transfer of rifapentine into 
breastmilk and expected levels are unknown at this stage (Egelund, et al., 2014). The overall accuracy 
ranged from 96.9% to 102.4% and 92.9% to 105.5% for rifapentine and 25-O-desacetyl rifapentine 
calibration standards, respectively. The Quality Controls accuracy ranged from 97.4% to 101.0% and 
99.1% to 106.0% for rifapentine and 25-O-desacetyl rifapentine, respectively. Other reported 
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analytical method validations for rifapentine are from total plasma and whole blood/DBS, which 
require a higher concentration range (Winchester, et al., 2015) (Parsons, et al., 2014).  
The method was shown to be specific and sensitive for rifapentine and 25-O-desacetyl rifapentine 
with no interfering peaks in the breastmilk samples. This was due to extensive sample clean-up that 
was effective for the method. There was also no significant carry-over on the Agilent autosampler 
observed for either rifapentine or 25-O-desacetyl rifapentine. 
Rifapentine and 25-O-desacetyl rifapentine were stable in human breastmilk for up to 72 hours at 
approximately -80°C and -20°C, on benchtop for ~4.5 hours on ice and after three freeze-thaw cycles.  
Parsons et al. and Winchester et al. similarly reported that three freeze-thaw cycles did not affect the 
stability of the analytes in plasma and whole blood DBS (Parsons, et al., 2014) (Winchester, et al., 
2015). Furthermore, it has been shown that concentrations of the analytes were not greatly affected 
after being at room temperature for at least 24 hours (Winchester, et al., 2015). 
The tested conditions were evaluated to mimic the handling of clinical samples during collection, 
transport, storage and analysis. Stored quality controls were analysed against a freshly prepared 
calibration curve. Fresh versus frozen experiments showed that freezing had no impact on stability of 
the analytes. Rifapentine and 25-O-desacetyl rifapentine were shown to be stable on-instrument over 
period of approximately 48 hours after which the entire batch could be reinjected. Autosampler 
stability revealed a decrease in peak area ratios, indicating that a partial batch cannot be reinjected 
after 48 hours in case of instrument failure. Future work should establish the absolute autosampler 
stability after 24 hours 
Stock solutions for Rifapentine and 25-O-desacetyl rifapentine were shown to be stable in methanol 
for up to 69 days at approximately -80°C, approximately 24 hours at -20°C (except for metabolite) and 
4°C. However, at room temperature for approximately 4 hours rifapentine and 25-O-desacetyl 
rifapentine were not stable. Future work will be to repeat on-bench stock solution test for 2-3 hours. 
Working solution stability yielded conflicting results and needs to be repeated in future as the results 
did not make scientific sense. Rifapentine at the low and high working stock solutions was stable at 
approximately -20°C. At approximately -80°C rifapentine was unstable at the low WS but was stable 
at -80°C of the high WS. Rifapentine at the low WS was stable at approximately 4°C and on ice at room 
temperature but was unstable under these conditions. At high WS stock, 25-O-desacetyl rifapentine 
was stable at 4°C, -20°C and -80°C but not at room temperature on-ice. Low WS stock of the metabolite 
was stable at room temperature on-ice, at 4°C and at -20°C, but failed at -80°C.   
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In summary the method is well suited for the analysis of rifapentine and 25-O-desaceetyl rifapentine 
in human breastmilk. This method will be utilized in the analysis of patient samples from a clinical 
study in South Africa in breastfeeding women with tuberculosis, it will assist in providing clinicians 
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